Page last updated: 2024-12-06

adefovir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Adefovir is a nucleoside analogue that acts as an antiviral agent. It is a prodrug that is converted in the body to its active metabolite, adefovir dipivoxil. Adefovir is used to treat chronic hepatitis B infection. The drug is often used in combination with other antiviral agents. The mechanism of action of adefovir involves inhibiting the activity of the viral DNA polymerase, thereby preventing viral replication. Adefovir is synthesized through a multi-step process involving the modification of the nucleoside adenine. The compound is studied due to its effectiveness in suppressing hepatitis B virus replication and its potential use in other viral infections.'

aurasperone A: isolated from Aspergillus aculeatus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aurasperone A : A dimeric naphthopyran with formula C32H26O10, originally isolated from Aspergillus niger. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

adefovir: inhibitor of African swine fever virus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3084216
CHEMBL ID450763
CHEBI ID133760
MeSH IDM0150266
PubMed CID60172
CHEMBL ID484
CHEBI ID134512
CHEBI ID2469
SCHEMBL ID49373
MeSH IDM0150266

Synonyms (105)

Synonym
b9ptq8z021 ,
unii-b9ptq8z021
(7,10'-bi-4h-naphtho(2,3-b)pyran)-4,4'-dione, 5,5'-dihydroxy-6,6',8,8'-tetramethoxy-2,2'-dimethyl-
aurasperone
15085-74-2
aurasperone a
CHEBI:133760
CHEMBL450763
5-hydroxy-7-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxobenzo[g]chromen-10-yl)-6,8-dimethoxy-2-methylbenzo[g]chromen-4-one
(7,10'-bi-4h-naphtho(2,3-b)pyran)-4,4'-dione, 5,5'-dihydroxy-6,6',8,8'-tetramethoxy-2,2'-dimethyl-, (7s)-
isoaurasperone a
DTXSID30164629
5-hydroxy-10-{5-hydroxy-6,8-dimethoxy-2-methyl-4-oxo-4h-benzo[g]chromen-7-yl}-6,8-dimethoxy-2-methyl-4h-benzo[g]chromen-4-one
5,5'-dihydroxy-6,6',8,8'-tetramethoxy-2,2'-dimethyl-7,10'-bi-4h-naphtho[2,3-b]pyran-4,4'-dione, 9ci
Q27274553
5-hydroxy-7-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxo-benzo[g]chromen-10-yl)-6,8-dimethoxy-2-methyl-benzo[g]chromen-4-one
AC-012
D02768
adefovir (usan/inn)
drg-0156
((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphonic acid
n-(2-phosphonylmethoxyethyl)adenine
phosphonic acid, ((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)-
9-(2-(phosphonomethoxy)ethyl)adenine
n-(2-phophonomethoxyethyl-2,6-diaminopurine)
brn 3561094
9-(2-phosphonomethoxyethyl)adenine
9-pmea
gs-0393 ,
9-(2-phosphorylmethoxyethyl)adenine
phosphonic acid, [[2-(6-amino-9h-purin-9-yl)ethoxy]methyl]-
gs 0393
2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid
gs 393
9-(2-phosphonylmethoxyethyl)adenine
106941-25-7
adefovir
pmea
NCGC00160539-01
hydrogen {[2-(6-amino-9h-purin-9-yl)ethoxy]methyl}phosphonate
CHEBI:134512
adefovir(1-)
CHEMBL484 ,
{[2-(6-amino-9h-purin-9-yl)ethoxy]methyl}phosphonic acid
9-[(2-phosphonylmethoxy)ethyl]adenine
[2-(6-amino-purin-9-yl)-ethoxymethyl]-phosphonic acid
[2-(6-amino-9h-purin-9-yl)ethoxy]methylphosphonic acid
9-[2-phosphonomethoxyethyl]adenine
[2-(6-amino-purin-9-yl)-ethoxymethyl]-phosphonic acid(pmea)
9-[3-(phosphonomethoxy)ethyl]adenine (pmea)
bdbm50001103
(2-(6-amino-9h-purin-9-yl)ethoxy)methylphosphonic acid
9-[2-(phosphonomethoxy)ethyl]adenine
(pmea)[2-(6-amino-purin-9-yl)-ethoxymethyl]-phosphonic acid
A801540
p-[[2-(6-amino-9h-purin-9-yl)ethoxy]methyl]-phosphonic acid
AKOS005259246
unii-6gqp90i798
adefovir [usan:inn:ban]
hsdb 8079
6gqp90i798 ,
tox21_111882
dtxsid6046214 ,
cas-106941-25-7
dtxcid4026214
5hg ,
amd3100 and pmea
FT-0601785
adefovir [who-dd]
[[2-(6-amino-9h-purin-9-yl)ethoxy]methyl]phosphonic acid
adefovir [mi]
adefovir [vandf]
adefovir [mart.]
adefovir [inn]
adefovir [usan]
S5068
SCHEMBL49373
KS-5018
SUPKOOSCJHTBAH-UHFFFAOYSA-N
NCGC00160539-02
Q-200594
mfcd00866943
p-[[2-(6-amino-9h-purin-9-yl)ethoxy]methyl]phosphonic acid
CHEBI:2469 ,
SR-01000945034-1
sr-01000945034
adefovir, >=98% (hplc)
BCP22955
Q353551
HY-B1826
CS-0013877
DB13868
((2-(6-amino-9h-purin-9-yl)ethoxy)-methyl)phosphonic acid
106941-25-7 (free acid)
pmea, gs-393, 9-(2-phosphonylmethoxyethyl)adenine
BA166179
EN300-6733813
SY015278
Z1741977297
adefovirum
j05af08
phosphonic acid, ((2-6-amino-9h-purin-9-yl)ethoxy)methyl
phosphonylmethoxyethyl-a
adefovir (mart.)
((2-6-amino-9h-purin-9-yl) ethoxy) methyl)- phosphonic acid.

Research Excerpts

Overview

Adefovir is an antiviral drug that exhibits high hydrophilic properties and negligible bioavailability (less than 12%). It is a potent nucleotide analog inhibitor of hepatitis B virus (HBV) DNA polymerase.

ExcerptReferenceRelevance
"Pradefovir is a liver targeted novel prodrug of adefovir (PMEA) developed to provide higher antiviral activity with reduced systemic toxicities. "( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020
)
1.54
"Adefovir is an antiviral drug that exhibits high hydrophilic properties and negligible bioavailability (less than 12%). "( Evaluation of Ion-pair Formation of Adefovir to Improve Permeation across Artificial and Biological Membranes.
Darsazan, B; Mortazavi, SA; Shafaati, A; Zarghi, A, 2018
)
2.2
"Adefovir is a potent nucleotide analog inhibitor of hepatitis B virus (HBV) DNA polymerase. "( Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells.
Birkus, G; Cihlar, T; Gibbs, CS, 2003
)
2.07
"Adefovir dipivoxil is a clinically approved drug that can block the action of an anthrax toxin."( Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.
Bergson, P; Gibbs, CS; Shen, Y; Soelaiman, S; Tang, WJ; Wang, CR; Zhukovskaya, NL; Zimmer, MI, 2004
)
1.3
"Adefovir is a nucleotide analog that has similar activity against wild-type and lamivudine-resistant HBV."( Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
Delaney, WE; Gibbs, CS; Miller, MD; Xiong, S; Yang, H, 2004
)
1.39
"Adefovir dipivoxil is an oral prodrug of adefovir."( Chronic hepatitis B--treatment with nucleoside analogues.
Leung, N, 2005
)
1.05
"Adefovir monotherapy is an established treatment modality for lamivudine-experienced patients with chronic hepatitis B, but it carries a significant risk of resistance in the long term. "( Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
Colombo, M; Iavarone, M; Lampertico, P; Manenti, E; Sablon, E; Viganò, M, 2007
)
2.12
"Adefovir is a nucleotide analog with anti-human immunodeficiency virus (HIV) activity that has been extensively studied in clinical trials. "( Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
Cihlar, T; Ho, ES; Mulato, AS, 2000
)
1.97

Effects

Adefovir dipivoxil has a very low rate of resistance, but there have been recent reports describing resistance mutations. AdefovIR has a good inhibitory effect against the latent or hidden HBV in neutrophils.

Adefovir has been shown to be effective in the treatment of lamivudine-resistant HBV in HIV/HBV-coinfected patients. The drug has a very low rate of resistance, but there have been reports describing resistance mutations.

ExcerptReferenceRelevance
"Adefovir has a good inhibitory effect against the latent or hidden HBV in neutrophils."( [Detection and analysis of HBV in polymorphonuclear neutrophils of patients with hepatitis B].
Han, Z; Wang, J, 2014
)
1.12
"Adefovir has a potent antiviral activity as a rescue treatment against lamivudine-resistant strains. "( Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha, CK; Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kwon, HC; Yoo, WD, 2009
)
2.02
"Adefovir dipivoxil has a very low rate of resistance, but there have been recent reports describing resistance mutations."( Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ, 2006
)
1.27
"Adefovir has a good inhibitory effect against the latent or hidden HBV in neutrophils."( [Detection and analysis of HBV in polymorphonuclear neutrophils of patients with hepatitis B].
Han, Z; Wang, J, 2014
)
1.12
"Adefovir has a potent antiviral activity as a rescue treatment against lamivudine-resistant strains. "( Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha, CK; Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kwon, HC; Yoo, WD, 2009
)
2.02
"Adefovir has been shown to be effective in the treatment of lamivudine-resistant HBV in HIV/HBV-coinfected patients."( Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Benhamou, Y, 2004
)
1.04
"Adefovir dipivoxil has been shown to be well tolerated in longterm therapy."( Chronic hepatitis B--treatment with nucleoside analogues.
Leung, N, 2005
)
1.05
"Adefovir dipivoxil has become a standard therapy for HBV infections, especially when resistant to lamivudine."( Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
De Clercq, E, 2007
)
1.06
"Adefovir dipivoxil has a very low rate of resistance, but there have been recent reports describing resistance mutations."( Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ, 2006
)
1.27
"Adefovir dipivoxil has been used alone or together with lamivudine to suppress lamivudine-resistant hepatitis B virus (HBV). "( Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Arnold, C; Dervisevic, S; Ijaz, S; Mechurova, J; Naoumov, NV; Tatman, N; Tedder, RS, 2008
)
2.03

Treatment

Adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations. overlap with surface gene mutations such as sW172stop/sL173F. Add-on treatment suppresses HBV replication more effectively than ETV or ADV monotherapy.

ExcerptReferenceRelevance
"Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels."( Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
Chang, KC; Chiu, KW; Chou, YP; Hsu, YC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014
)
1.47
"In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported."( Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.
Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010
)
1.12
"Adefovir add-on treatment in patients with LAM-resistant CHB suppresses HBV replication more effectively than ETV or ADV monotherapy. "( Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Cho, YK; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JH; Sohn, CI, 2010
)
2.02
"The adefovir treatment group included 32 patients, who were administrated adefovir dipivoxil 10 mg/d."( [Efficacy of two nucleoside analogs to treat resistant HBeAg-negative chronic hepatitis B].
Li, XJ; Shu, X; Xu, QH; Zhu, JY, 2011
)
0.85
"Adefovir/lamivudine treatment resulted in greater viraemia reduction than adefovir monotherapy."( Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Arnold, C; Dervisevic, S; Ijaz, S; Mechurova, J; Naoumov, NV; Tatman, N; Tedder, RS, 2008
)
1.31
"Adefovir treatment began after the development of graft failure."( Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir.
Cane, P; Feraz-Neto, BH; Harrison, R; Mutimer, D; O'Donnell, K; Pillay, D; Shaw, J, 2001
)
1.24

Toxicity

CXCR4 antagonist plerixafor (AMD3100) alone or combination with adefovir (PMEA, 9-(2-phosphonylmethoxyethyl)adenine) safe and effective for treating FIV-infected cats.

ExcerptReferenceRelevance
" Repeat infusions of PMEA at a dose of 1000 mg were safe and well tolerated."( Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study.
Arends, S; Kamp, W; Schokker, J; van Halteren, E, 1996
)
0.29
"This report investigates the pathomechanism of acute renal failure caused by toxic acute tubular necrosis after treatment with the antiretroviral agent adefovir."( Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.
Bell, A; D'agati, VD; Kambham, N; Markowitz, GS; Tanji, K; Tanji, N, 2001
)
1.95
"We have demonstrated that low-dosage adefovir therapy in kidney-transplant patients is relatively safe as far as renal parameters are concerned, even though we observed a slight impairment of renal proximal-tubular function."( Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients.
Alric, L; Huart, A; Izopet, J; Kamar, N; Rostaing, L; Tack, I, 2009
)
0.94
" Adverse event rates were comparable between groups."( Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011
)
0.64
"CXCR4 antagonist plerixafor (AMD3100, 1,1'-bis-1,4,8,11-tetraazacyclotetradekan) alone or combination with adefovir (PMEA, 9-(2-phosphonylmethoxyethyl)adenine) safe and effective for treating FIV-infected cats."( Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats.
Balzarini, J; Egberink, H; Hartmann, K; Klein, D; Stengel, C,
)
0.34
" In conclusion, a combination of LAM and ADV initiated at the time of wait listing provides safe and effective protection against recurrent HBV infection without the high costs and inconvenience associated with long-term HBIG therapy."( Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Angus, PW; Gane, EJ; McCaughan, GW; Patterson, S; Strasser, SI, 2013
)
0.68
" These findings suggest that HIV-infected cancer patients receiving nelfinavir might experience both enhanced antitumor efficacy and unexpected adverse toxicity given the role of MRP4/ABCC4 in exporting nucleoside-based antiretroviral medications and cancer chemotherapeutics."( Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Ambudkar, SV; Cheepala, SB; Ekins, S; Fukuda, Y; Schuetz, JD; Sparreboom, A; Takenaka, K; Wu, CP, 2013
)
0.39
" Patients underwent serological analysis at 3-6 month intervals during treatment and follow-up to evaluate occurrence of adverse events; serological parameters included blood count, markers of liver, kidney and thyroid function, and levels of autoantibodies and creatine kinase."( [Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients].
Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, YH, 2013
)
0.63
" The occurrences of adverse events were similar at week 48 and week 96."( [Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients].
Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, YH, 2013
)
0.63
"This retrospective investigation carried out in Guangdong Province indicated that not only are anti-HBV drugs efficacious for blocking vertical transmission of HBV but also are safe for both mothers and infants when taken by fathers or mothers during the reproduction phases of insemination and pregnancy."( [Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province].
Chen, X; Gao, W; Li, D; Peng, J; Wen, F; Xia, J; Xu, C; Xu, M; Yao, Z, 2014
)
0.4
"One of the most common in vitro assays to evaluate the probability of a compound to cause adverse effects is a cytotoxicity assay."( Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir.
Leach, KL; Piotrowski, M; Wang, R; Zhang, H; Zhang, X, 2015
)
0.66
" Often, renal adverse effects are recognized only during clinical stages of drug development."( A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity.
Hilgendorf, C; Jansen, K; Masereeuw, R; Nieskens, TT; Peters, JG; Röring, M; Schreurs, MJ; Smits, N; van der Made, TK; Wilmer, MJ; Woestenenk, R, 2016
)
0.43
"To improve biosafety of clinical analysis, we used antiviral drugs of adefovir and tenofovir as model drugs and developed a safe pretreatment method combining sealing technique with direct injection technique."( A novel pretreatment method combining sealing technique with direct injection technique applied for improving biosafety.
An, J; Du, C; Gao, JL; Jiang, Y; Li, M; Ma, H; Wang, X; Zhang, L, 2017
)
0.69
"Our results demonstrate the efficacy of switching to TDF monotherapy in virologically suppressed CHB patients receiving long-term LAM+ADV therapy, with a low rate of adverse events."( Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A, 2017
)
0.7
" In this report, we use metabolomics and proteomics with HK-2 cells and animal models to dissect the molecular pathways underlying nephropathy caused by TFV and its more toxic analog, adefovir (ADV)."( Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.
Chen, J; Chen, L; Cheng, L; Chi, W; Deng, H; Huo, Y; Lan, Z; Liu, X; Siegenthaler, JA; Song, W; Sun, K; Xu, L; Zhao, X, 2017
)
1.01
" No subject experienced a serious adverse event or nephrotoxicity."( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020
)
0.82

Pharmacokinetics

The developed method was successfully applied to the pharmacokinetic study of following oral administration of pradefovir mesylate (10, 30, 60, 90 and 120 mg) and adefovir dipivoxil (10 mg) The half-life of PMEA in the pradeFovir group was 11.

ExcerptReferenceRelevance
" Pharmacokinetic experiments with mice showed that the oral bioavailabilities of PMEA following oral gavage of bis(POM)-PMEA, diphenyl-PMEA, or PMEA (at a dose equivalent to 50 mg of PMEA per kg) were 53,3, and 16%, respectively."( Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Balzarini, J; Bischofberger, N; De Clercq, E; Naesens, L, 1996
)
0.29
" Intracellular activation of a small fraction (< 10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies."( Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Cundy, KC, 1999
)
0.53
" Pharmacokinetic experiments in mice showed that the oral bioavailabilities of PMEA following oral gavage of Bis-PMEA or PMEA (at a dose equivalent to 28 mg of PMEA/kg) were 50."( Pharmacokinetic and antiretroviral activity in mice of oral [P(1),P(2)-bis[2-(adenin-9-yl)ethoxymethyl]phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Cappellacci, L; Casabianca, A; Celeste, AG; Cerasi, A; Chiarantini, L; Dominici, S; Franchetti, P; Grifantini, M; Magnani, M; Rossi, L; Serafini, S, 2002
)
0.31
" The validated LC/MS/MS method has been successfully used in a pharmacokinetic study in healthy volunteers treated with oral adefovir dipivoxil at 10 and 20 mg."( Determination of adefovir in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study.
Bi, HC; Chen, X; Huang, M; Zhong, GP; Zhou, S, 2005
)
0.87
" Pharmacokinetic assessments were performed on days 4 and 24 for adefovir and on days 14 and 24 for entecavir."( Absence of a pharmacokinetic interaction between entecavir and adefovir.
Bifano, M; Grasela, DM; LaCreta, F; Smith, RA; Yan, JH; Zhang, D, 2007
)
0.82
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The following pharmacokinetic parameters were elucidated after administering a single dose of 10 mg, 20 mg, and 30 mg of adefovir dipivoxil."( Determination of adefovir by LC-ESI-MS-MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Dai, L; Di, B; Ding, L; Fan, H; Xiao, D; Zhang, J; Zhu, Y; Zou, J,
)
0.68
"A selective, rapid and sensitive hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) method was developed for the first time to determine adefovir in human plasma and applied to a pharmacokinetic study."( Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of adefovir in human plasma and its application to a pharmacokinetic study.
Li, F; Qin, F; Qin, T; Xiong, Z; Yang, S; Zhang, Y, 2010
)
0.77
" Mean HBIg half-life was 21."( Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
Andreone, P; Bacci, M; Burra, P; Canova, D; Cursaro, C; Fiorentino, B; Guazzini, S; Marengo, A; Marzano, A; Riili, A; Volpes, R, 2010
)
0.36
" Anti-HBs titers three times higher than aimed and four weeks mean half-life could suggest the reduction of doses and the elongation of the interval of administration of im-HBIg."( Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
Andreone, P; Bacci, M; Burra, P; Canova, D; Cursaro, C; Fiorentino, B; Guazzini, S; Marengo, A; Marzano, A; Riili, A; Volpes, R, 2010
)
0.36
" The method was applied to the determination of adefovir in plasma from 12 subjects dosed with adefovir 2 x 10 mg tablets and pharmacokinetic parameters were evaluated."( Rapid high-performance liquid chromatographic method for determination of adefovir in plasma using UV detection: application to pharmacokinetic studies.
Foroutan, SM; Khoddam, A; Movahed, H; Shafaati, A; Zarghi, A, 2011
)
0.86
" The developed method was successfully applied to the pharmacokinetic study of following oral administration of single dose of pradefovir mesylate (10, 30, 60, 90 and 120 mg) and adefovir dipivoxil (10 mg) to healthy Chinese volunteers."( Development and Validation of a Sensitive LC-MS-MS Method for the Determination of Adefovir in Human Serum and Urine: Application to a Clinical Pharmacokinetic Study.
Shen, L; Xiao, QQ; Yang, J; Zhan, Y; Zhang, Y, 2016
)
0.86
" The half-life of PMEA in the pradefovir group was 11."( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020
)
1.1

Compound-Compound Interactions

The study aimed to investigate the efficacy and safety of peginterferon α-2a in combination with lamivudine or adefovir in the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB)

ExcerptReferenceRelevance
" Adefovir and PMPA both demonstrated strong synergistic anti-HIV activity in combination with AZT."( Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Cherrington, JM; Mulato, AS, 1997
)
1.53
" These drug-drug interactions were not expected, the mechanism(s) is (are) not clear, and additional studies are warranted."( Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Acosta, EP; Cheng, H; Fischl, M; Fletcher, CV; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Mills, C; Raasch, R; Remmel, RP, 2000
)
0.31
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
" We investigated the activity of clevudine (CLV) in combination with other nucleoside/nucleotide analogues to determine if these combinations were compatible in vitro."( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010
)
0.36
"Using the HepAD38 cell line, which expresses wild-type HBV, and a real-time PCR assay, we tested the anti-HBV activity of CLV in combination with entecavir, lamivudine, adefovir, tenofovir and telbivudine (TBV)."( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010
)
0.56
"When CLV was combined with entecavir, lamivudine, adefovir or tenofovir, a synergistic antiviral effect was observed; however, the combination of CLV and TBV gave an antagonistic antiviral response."( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010
)
0.61
"Entecavir combined with adefovir is an effective rescue therapy in CHB patients after failure of treatment with nucleoside analogs."( [Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment].
Guo, YB; Hou, JL; Peng, J; Sun, J; Wang, ZH; Yan, L; Yang, J; Zhou, B, 2011
)
0.93
"The study aimed to investigate the efficacy and safety of peginterferon α-2a (PEG IFNα-2a) in combination with lamivudine or adefovir in the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB)."( Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao, ZH; Chen, XY; Liu, YL; Ma, LN; Zhang, HW, 2013
)
0.83
" This study suggests the proof-of-concept that the lower dose of NA in combination with other NA might be the theoretical option for rescue combination therapy in patients with CHB who had failed on prior multiple NA treatments in order to reduce systemic exposure and possible side effects of NA."( Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments.
Cho, Y; Kim, YJ; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2015
)
0.65
"Our results demonstrate that apigenin regulates OAT1, and can cause TDI or herb-drug interaction (HDI) when used in combination with acyclovir or adefovir."( Apigenin, a novel candidate involving herb-drug interaction (HDI), interacts with organic anion transporter 1 (OAT1).
Cao, Y; Chen, J; Fu, W; Li, H; Pang, J; Wu, T; Zhou, P, 2017
)
0.66
"As a tool to be used in transporter-mediated drug-drug interaction studies, a sensitive LC-MS/MS method for the simultaneous quantification of adefovir and pitavastatin in human plasma and adefovir in urine was developed and successfully validated."( Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies.
Fuhr, U; Kinzig, M; Scherf-Clavel, O; Sörgel, F; Stoffel, MS, 2019
)
1.05

Bioavailability

The lead prodrug (14, MB06866, pradefovir) exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP. Additional studies will be needed to determine whether a similar mutation in HIV RT develops in patients receiving PMEA or its orally bioavailable prodrug adefovir dipivoxil.

ExcerptReferenceRelevance
"A number of esters and amides of the anti-HIV nucleotide analogue 9-[2-(phosphonomethoxy)-ethoxy]adenine (1) have been synthesized as potential prodrugs and evaluated for oral bioavailability in mice."( Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine.
Ashton, RJ; Bailey, S; Harnden, MR; Jackson, SM; Serafinowska, HT; Sutton, D, 1995
)
0.29
"The bioavailability of PMEA from three oral formulations of the prodrug bis(POM)-PMEA has been evaluated in fasted male cynomolgus monkeys."( Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys.
Cundy, KC; Fishback, JA; Lee, ML; Lee, WA; Shaw, JP; Soike, KF; Visor, GC, 1994
)
0.29
"A series of phosphonate prodrugs were evaluated in an attempt to increase the oral bioavailability of the anti-HIV agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA; 1)."( Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Hitchcock, MJ; Mansuri, MM; Martin, JC; Russell, J; Starrett, JE; Tortolani, DR; Whiterock, V, 1994
)
0.29
" The oral bioavailability of PMEA in this species (4."( Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys.
Cundy, KC; Lee, WA; Shaw, JP, 1994
)
0.29
"The pharmacokinetics and bioavailability of adefovir [9-[2-(phosphonomethoxy)ethyl]adenine] were examined at two dose levels in three phase I/II studies in 28 human immunodeficiency type 1-infected patients."( Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.
Barditch-Crovo, P; Collier, AC; Cundy, KC; Ebeling, D; Jaffe, HS; Toole, J; Walker, RE, 1995
)
0.84
" Taken together, these promising findings suggest that an orally bioavailable prodrug of MDL 74,968 should be developed for the treatment of HIV infection."( MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.
Ahmed, PS; Brennan, TM; Bridges, CG; Casara, P; Hornsperger, JM; Navé, JF; Taylor, DL; Tyms, AS, 1996
)
0.29
", bis(pivaloyloxymethyl)-PMEA [bis(POM)-PMEA] and diphenyl-PMEA, have been synthesized in an attempt to increase the oral bioavailability of this broad-spectrum antiviral agent."( Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Balzarini, J; Bischofberger, N; De Clercq, E; Naesens, L, 1996
)
0.29
" Additional studies will be needed to determine whether a similar mutation in HIV RT develops in patients receiving PMEA or its orally bioavailable prodrug adefovir dipivoxil (bis-POM PMEA)."( In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Anderson, B; Cherrington, JM; Foli, A; Gu, Z; Kavlick, M; Mitsuya, H; Saville, MW; Sogocio, KM; Wainberg, MA; Yarchoan, R, 1996
)
0.49
"A new series of hitherto unknown 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) phosphonodiester derivatives incorporating carboxyesterase-labile S-acyl-2-thioethyl (SATE) moieties as transient phosphonate-protecting groups was prepared in an attempt to increase the oral bioavailability of the antiviral agent PMEA."( Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
Aubertin, AM; Benzaria, S; Gosselin, G; Imbach, JL; Johnson, R; Maury, G; Obert, G; Pélicano, H, 1996
)
0.29
"The oral bioavailability of PMEA [9-[2-(phosphonomethoxy)ethyl]adenine; adefovir) has been determined in rats from three bisester prodrugs of PMEA: bis-(pivaloyloxymethyl) PMEA (bis-POM PMEA), bis-(phenyl) PMEA, and bis-(o-ethoxyphenyl) PMEA."( Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats.
Arimilli, MN; Bidgood, AM; Cundy, KC; Jones, RJ; Krishnamurthy, VV; Lee, WA; Louie, MS; Shaw, JP, 1997
)
0.53
" Adefovir dipivoxil, an orally bioavailable prodrug of adefovir is currently in phase III clinical trials for the treatment of HIV and phase II clinical trials for the treatment of HBV infections."( Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Cherrington, JM; Mulato, AS, 1997
)
1.53
" Cidofovir and adefovir are dianionic at physiological pH and have low oral bioavailability in animals and humans."( Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Cundy, KC, 1999
)
0.88
" In the present study, the synthesis, oral bioavailability and antiretroviral activity of a new prodrug of PMEA, consisting of two molecules of PMEA bound together by a P-O-P bond (Bis-PMEA), are reported."( Pharmacokinetic and antiretroviral activity in mice of oral [P(1),P(2)-bis[2-(adenin-9-yl)ethoxymethyl]phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Cappellacci, L; Casabianca, A; Celeste, AG; Cerasi, A; Chiarantini, L; Dominici, S; Franchetti, P; Grifantini, M; Magnani, M; Rossi, L; Serafini, S, 2002
)
0.31
" The lead prodrug (14, MB06866, pradefovir), identified from a variety of in vitro and in vivo assays, exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP."( Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Boyer, SH; Colby, TJ; Craigo, W; DaRe, J; Erion, MD; Fujitaki, JM; Gómez-Galeno, JE; Matelich, MC; Ollis, K; Reddy, KR; Sun, Z; Ugarkar, BG; van Poelje, PD, 2008
)
1.35
" HDP-(S)-HPMPA is orally bioavailable and provides excellent liver exposure to the drug."( Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
Beadle, JR; Hostetler, KY; Korba, BE; Morrey, JD; Wyles, DL, 2009
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Importantly, the total area under the plasma concentration-time curve from time zero to time infinity (AUC), peak plasma concentration (Cmax) and extent of absolute oral bioavailability (F) of adefovir after oral administration of adefovir dipivoxil were significantly higher in 1,25(OH)2D3-treated rats than in control rats."( Effects of 1α,25-Dihydroxyvitamin D3 on Intestinal Absorption and Disposition of Adefovir Dipivoxil and Its Metabolite, Adefovir, in Rats.
Choi, MK; Kim, SB; Maeng, HJ; Son, JH; Yoon, IS, 2015
)
0.83
" The most advantageous pharmacokinetic profile and the best oral bioavailability were found in tyrosinebased prodrugs."( Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals.
Krecmerova, M, 2017
)
0.46
"Adefovir is an antiviral drug that exhibits high hydrophilic properties and negligible bioavailability (less than 12%)."( Evaluation of Ion-pair Formation of Adefovir to Improve Permeation across Artificial and Biological Membranes.
Darsazan, B; Mortazavi, SA; Shafaati, A; Zarghi, A, 2018
)
2.2
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Adefovir dipivoxil is dosed at submaximally efficacious doses because of renal toxicity. The enzyme induction potential of pradefovir was evaluated in rats following multiple oral dosing and in primary cultures of human hepatocytes.

ExcerptRelevanceReference
" The persistence of activated metabolites suggests that infrequent dosing may be possible due to a prolonged antiviral effect."( Biochemical pharmacology of acyclic nucleotide analogues.
Bronson, JJ; De Boeck, H; Ghazzouli, I; Hitchcock, MJ; Ho, HT; Martin, JC; Woods, K, 1990
)
0.28
" While the infrequent dosage regimen increased the anti-retrovirus activity of PMEA, it did not increase its toxicity for the host."( Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered.
Balzarini, J; De Clercq, E; Naesens, L, 1990
)
0.28
" (S)-HPMPA inhibited the development of tail lesions caused by vaccinia virus if it was administered intraperitoneally or subcutaneously at a dosage as low as 5 mg/kg per day."( Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.
De Clercq, E; Holý, A; Rosenberg, I, 1989
)
0.28
" Oral dosing with bis(alkyl) phosphonates 3a,b resulted in apparent absorption of the prodrugs (> or = 40%), although neither of the esters were completely cleaved to liberate the parent phosphonate PMEA."( Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Hitchcock, MJ; Mansuri, MM; Martin, JC; Russell, J; Starrett, JE; Tortolani, DR; Whiterock, V, 1994
)
0.29
" Nine cats received PMEA at a dosage of 10 mg/kg body weight, nine cats received FPMPA at a dosage of 25 mg/kg body weight."( [Comparative investigation of the efficacy of two nucleocapsid analogs in FIV infected cats].
Balzarini, J; Erfle, V; Goebel, F; Goldberg, M; Hartmann, K; Kuffer, M; Rolinski, B, 1997
)
0.3
" Likewise, a clear dose-response relationship was established for the in vivo antitumor activity of PMEA in choriocarcinoma-bearing rats."( In vitro and in vivo inhibitory activity of the differentiation-inducing agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against rat choriocarcinoma.
Balzarini, J; De Clercq, E; Degrève, B; Hatse, S; Naesens, L; Vandeputte, M; Waer, M, 1998
)
0.3
" Eight Pekin-Aylesbury ducks congenitally infected with the duck hepatitis B virus (DHBV) were treated with PMEA at a dosage of 15 mg/kg of body weight/day via the intraperitoneal route for 4 weeks."( Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.
Angus, PW; Colledge, DL; Locarnini, SA; Nicoll, AJ; Smallwood, RA; Toole, JJ, 1998
)
0.3
" Both prophylactic and therapeutic dosing regimens were effective."( Chemokines, nitric oxide and antiarthritic effects of 9-(2-phosphonomethoxyethyl)adenine (Adefovir).
Franková, D; Holý, A; Zídek, Z, 1999
)
0.52
" The effect of more frequent dosing requires further evaluation."( Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results of a phase I/II study.
Boucher, CA; Cambridge, E; De Groot, T; De Jong, S; Kamp, W; Schokker, J; Schuurman, R, 1999
)
0.64
"The pharmacokinetics of pradefovir and adefovir, 9-(2-phosphonylmethoxyethyl) adenine (PMEA), was evaluated in healthy male volunteers after oral dosing of pradefovir (10, 30, or 60 mg)."( Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir.
Lin, CC; Peterson, J; Teng, A; Xu, C; Yeh, LT, 2005
)
0.94
" The enzyme induction potential of pradefovir was evaluated in rats following multiple oral dosing and in primary cultures of human hepatocytes."( Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.
Benetton, S; Fang, C; Lin, CC; Xu, GF; Yeh, LT, 2006
)
0.91
"Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity."( Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Boyer, SH; Colby, TJ; Craigo, W; DaRe, J; Erion, MD; Fujitaki, JM; Gómez-Galeno, JE; Matelich, MC; Ollis, K; Reddy, KR; Sun, Z; Ugarkar, BG; van Poelje, PD, 2008
)
2.51
" Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dosing schemes."( Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation.
Hadem, J; Hooman, N; Klempnauer, J; Manns, MP; Philipp, G; Priess, A; Rifai, K; Rosenau, J; Tillmann, HL; Vaske, B, 2008
)
0.35
" To attain a better antiviral response the dosage of entecavir was increased to 2mg daily in two patients, resulting in further viral load decline for both of them."( Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M, 2009
)
0.57
"Entecavir monotherapy dosed at 1mg resulted in a slow reduction of viral load in both lamivudine-experienced and -naïve patients with persistently high HBV DNA during adefovir therapy."( Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M, 2009
)
0.76
" IFN therapy requires dosage reduction and close monitoring in patients with a GFR <50 ml/min/1."( Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Bob, F; Bozdog, G; Cioca, D; Curescu, M; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Petrica, L; Sporea, I; Velciov, S; Vernic, C, 2011
)
0.37
" The method was applied to the determination of adefovir in plasma from 12 subjects dosed with adefovir 2 x 10 mg tablets and pharmacokinetic parameters were evaluated."( Rapid high-performance liquid chromatographic method for determination of adefovir in plasma using UV detection: application to pharmacokinetic studies.
Foroutan, SM; Khoddam, A; Movahed, H; Shafaati, A; Zarghi, A, 2011
)
0.86
"NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50 mL/min."( Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014
)
0.4
" Antiviral treatments were withdrawn in patients who met all of the following 7 criteria: (i) no clinical and histologic evidence of cirrhosis, (ii) normal liver biochemistry, (iii) negative for both HBV DNA and hepatitis B envelope antigen (HBeAg), (iv) no resistance to antiviral agent, (v) antiviral therapy > 9 months, (vi) maintenance dosage of immunosuppressant for > 3 months, and (vii) no history of acute rejection during recent 6 months."( Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho, JH; Choi, JY; Huh, S; Kang, YJ; Kim, CD; Kim, HK; Kim, JS; Kim, YL; Kwon, O; Lim, JH; Park, GY; Park, SH, 2014
)
0.4
"In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at a dosage of 10 mg/day for a median of 33 months in this multicenter cohort study."( Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.
Cho, M; Choi, JY; Han, KH; Hwang, JS; Kim, BI; Kim, DJ; Lee, CK; Lee, HJ; Paik, SW; Suh, DJ; Um, SH; Woo, HY; Yoon, SK, 2014
)
0.73
"The difference in binding affinity of tenofovir (more than two orders of magnitude in terms of local concentration), a 30x higher dosage of the (R)-tenofovir enantiomer as compared to conformational isomeric or rotameric adefovir, and the constrained mutational space due to gene overlap in HBV may explain the absence of resistance mutations after 6 years of tenofovir monotherapy."( Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.
Berkhout, B; van Hemert, FJ; Zaaijer, HL, 2014
)
0.86
" Monitoring of renal function showed no case of the Fanconi syndrome, no significant alterations of median serum creatinine, eGFR and phosphate levels, although a reduction of TDF dosage was required in five patients (8."( Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A, 2017
)
0.7
" Indeed, achieving the desired therapeutic outcome in the absence of an effective means of targeted delivery must rely on dosage escalation, which frequently causes severe toxicity."( Overcoming the Hydrolytic Lability of a Reaction Intermediate in Production of Protein/Drug Conjugates: Conjugation of an Acyclic Nucleoside Phosphonate to a Model Carrier Protein.
Kaltashov, IA; Xu, S, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
HIV-1 reverse transcriptase inhibitorAn entity which inhibits the activity of HIV-1 reverse transcriptase.
drug metabolitenull
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
nephrotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the kidney in animals.
DNA synthesis inhibitorAny substance that inhibits the synthesis of DNA.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (10)

ClassDescription
biarylAn organic aromatic compound whose structure contains two aromatic rings or ring systems, joined to each other by a single bond.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
cyclic ketone
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
organooxygen heterocyclic antibiotic
naphtho-gamma-pyroneAny naphthopyran whose skeleton consists of a naphathalene ring system ortho-fused to a gamma-pyrone.
6-aminopurinesAny compound having 6-aminopurine (adenine) as part of its structure.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
phosphonic acidsHP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Adefovir Dipivoxil Metabolism Pathway46

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency3.98110.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency5.30800.000323.4451159.6830AID743065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine deaminase Bos taurus (cattle)Ki800.00000.00000.48937.0000AID33683
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)28.00000.27004.53069.9000AID681331
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Capsid protein Hepatitis B virusEC50 (µMol)0.08270.00020.26030.8194AID1363957
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Km270.00000.57001.33502.1000AID679147
Solute carrier family 22 member 6Homo sapiens (human)Km25.86670.42004.61839.3000AID544648; AID678820; AID679323
Solute carrier family 22 member 8Homo sapiens (human)Km1,220.00000.34501.32173.1000AID544649
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
bone developmentPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic processPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
purine nucleotide biosynthetic processPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
ADP biosynthetic processAdenylate kinase isoenzyme 1Homo sapiens (human)
nucleoside triphosphate biosynthetic processAdenylate kinase isoenzyme 1Homo sapiens (human)
nucleobase-containing small molecule interconversionAdenylate kinase isoenzyme 1Homo sapiens (human)
AMP metabolic processAdenylate kinase isoenzyme 1Homo sapiens (human)
ATP metabolic processAdenylate kinase isoenzyme 1Homo sapiens (human)
nucleoside monophosphate phosphorylationAdenylate kinase isoenzyme 1Homo sapiens (human)
ADP biosynthetic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleobase-containing small molecule interconversionAdenylate kinase 2, mitochondrialHomo sapiens (human)
AMP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleoside monophosphate phosphorylationAdenylate kinase 2, mitochondrialHomo sapiens (human)
adenosine catabolic processAdenosine deaminase Bos taurus (cattle)
cell adhesionAdenosine deaminase Bos taurus (cattle)
nucleotide metabolic processAdenosine deaminase Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic processAdenosine deaminase Bos taurus (cattle)
inosine biosynthetic processAdenosine deaminase Bos taurus (cattle)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
magnesium ion bindingPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
enzyme inhibitor activityPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
protein bindingPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
identical protein bindingPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
ATP bindingPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
ribose phosphate diphosphokinase activityPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
adenylate kinase activityAdenylate kinase isoenzyme 1Homo sapiens (human)
nucleoside diphosphate kinase activityAdenylate kinase isoenzyme 1Homo sapiens (human)
ATP bindingAdenylate kinase isoenzyme 1Homo sapiens (human)
nucleoside triphosphate adenylate kinase activityAdenylate kinase isoenzyme 1Homo sapiens (human)
adenylate kinase activityAdenylate kinase 2, mitochondrialHomo sapiens (human)
protein bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
adenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
protein bindingAdenosine deaminase Bos taurus (cattle)
zinc ion bindingAdenosine deaminase Bos taurus (cattle)
2'-deoxyadenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
ribose phosphate diphosphokinase complexPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
cytoplasmPhosphoribosyl pyrophosphate synthase-associated protein 2Homo sapiens (human)
outer dense fiberAdenylate kinase isoenzyme 1Homo sapiens (human)
cytosolAdenylate kinase isoenzyme 1Homo sapiens (human)
extracellular exosomeAdenylate kinase isoenzyme 1Homo sapiens (human)
cytoplasmAdenylate kinase isoenzyme 1Homo sapiens (human)
cytosolAdenylate kinase isoenzyme 1Homo sapiens (human)
mitochondrial intermembrane spaceAdenylate kinase 2, mitochondrialHomo sapiens (human)
extracellular exosomeAdenylate kinase 2, mitochondrialHomo sapiens (human)
sperm mitochondrial sheathAdenylate kinase 2, mitochondrialHomo sapiens (human)
cytoplasmAdenylate kinase 2, mitochondrialHomo sapiens (human)
mitochondrionAdenylate kinase 2, mitochondrialHomo sapiens (human)
lysosomeAdenosine deaminase Bos taurus (cattle)
cytoplasmic vesicle lumenAdenosine deaminase Bos taurus (cattle)
anchoring junctionAdenosine deaminase Bos taurus (cattle)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (379)

Assay IDTitleYearJournalArticle
AID1777026Anticancer activity against cisplatin-resistant human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of cisplatin by MTT assay
AID332327Inhibition of human telomerase activity by TRAP assay2003Journal of natural products, Jan, Volume: 66, Issue:1
New dimeric naphthopyrones from Aspergillus niger.
AID332329Inhibition of human telomerase activity at 100 ug/mL by TRAP assay2003Journal of natural products, Jan, Volume: 66, Issue:1
New dimeric naphthopyrones from Aspergillus niger.
AID332328Inhibition of Taq polymerase in RNase treated human HT1080 cells at 100 ug/mL by PCR2003Journal of natural products, Jan, Volume: 66, Issue:1
New dimeric naphthopyrones from Aspergillus niger.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID679323TP_TRANSPORTER: uptake in OAT1-expressing CHO cells2000Journal of the American Society of Nephrology : JASN, Mar, Volume: 11, Issue:3
Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.
AID405412Antiviral activity against PERV infected in human 293T cells assessed as inhibition of proximal DNA synthesis after 24 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID611767Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID523464Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA level at 5.9 uM after 72 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID618325Antiviral activity against HIV1 clade C isolate 2914 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1126841Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID618319Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID374204Cytotoxicity against human PHK assessed as minimum cytotoxic concentration required for alteration in cell morphology after 4 days by microscopy2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID446159Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg level after 9 days by ELISA2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.
AID611624Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopy2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID83262Inhibition of cytopathogenicity against human HIV-2(LAV-2) in MT-4 cells2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID324769Selectivity index, ratio of CC50 for african green monkey BSC1 cells ot EC50 for Simian virus 40 PML1 EK2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID734077Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 9 days by fluorescence PCR method2013European journal of medicinal chemistry, Apr, Volume: 62Anti-hepatitis B virus and anti-cancer activities of novel isoflavone analogs.
AID618315Cytotoxicity against human CEM cells2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID45040Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID275081Stability in pH 9.0 buffer at 37 degC after 72 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID626001Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID106398Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-1(IIIb) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID268269Selectivity index, CC50 for HepG2.2.15 cells/IC50 for HBV2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives.
AID625932Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID618518Cytotoxicity against human HepAD38 cells2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID106393Compound was tested in vitro for Minimum inhibitory concentration required to reduce CMV(AD-169) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID611622Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID1186715Activity of recombinant AK1 (unknown origin) assessed as ADP formation by spectroscopic pyruvate kinase/lactate dehydrogenase coupled assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588979Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP42010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID105588Cellular toxic effect was determined in MT-4 cells2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID611762Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID47263In vitro antiviral activity against HIV-2 in CEM cells2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID374201Selectivity index, ratio of CC50 for human PHK to EC50 for Camelpox virus CML1 infected in human PHK2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID90940Antiviral activity against HCMV was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
AID625997Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant to EC90 for wild type Hepatitis B virus2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID681331TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID105986Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-2.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID157044Inhibitory activity against PRPP synthetase2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID374194Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID625937Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant to EC90 for wild type Hepatitis B virus2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID544666Activity of human OAT1 transfected in CHO cells measured per 10'6 cells2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID374202Selectivity index, ratio of CC50 for human PHK to EC50 for Camelpox virus CML14 infected in human PHK2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID105556In vitro antiviral activity against HIV-2 in MT-4 cells2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID626003Fold resistance, ratio of EC90 for adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant to EC90 for wild type Hepatitis B virus2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID33683Inhibitory activity against adenosine deaminase2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID588964Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID609585Antiviral activity against Human immunodeficiency virus type1 3B infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopic analysis2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity.
AID611768Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID618450Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1186716Activity of recombinant AK2 (unknown origin) assessed as ADP formation by spectroscopic pyruvate kinase/lactate dehydrogenase coupled assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID268267Inhibition of HBV DNA replication2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID218360Compound was tested for antiviral activity against the Vero cells infected with HSV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID374199Antiviral activity against Camelpox virus CML14 infected in human PHK assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID1192801Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID626005Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative So2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1192802Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID618317Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID324757Antiviral activity against Murine polyomavirus 2PTA2 in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID523461Decrease in HscA70-mRNA expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 5.9 uM after 24-36 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID46195Inhibition of Human immunodeficiency virus (HIV)-2 ROD strain induced cytopathicity in CEM cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID83510Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) YS strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID1192804Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID157045Michaelis rate constant is determined by the Lineweaver and Burk method against PRPP synthetase2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID106407Minimum inhibitory concentration required to reduce VZV TK-(07-1) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID82695Inhibition of Thymidine kinase deficient (TK-) Varicella-Zoster virus (VZV) YS/R strain induced cytopathicity in HEL cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID84422Inhibitory effect on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 100 mk/kg/day2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID618320Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1636523Oral bioavailability in rhesus monkey by HPLC analysis2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID82696Inhibition of Varicella-Zoster virus (VZV) OKA strain induced cytopathicity in HEL cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID324759Cytotoxicity against mouse UC1B cells2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID310044Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID365176Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID374197Selectivity index, ratio of CC50 for HEL299 cells to EC50 for Camelpox virus CML14 infected in HEL299 cells2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID106404Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK+(YS) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID611623Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID1062054Antiviral activity against Herpes simplex virus 2 G2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID1192806Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as viral DNA replication after 9 days by real-time PCR analysis (Rvb = 6.12 +/- 1.46 AU)2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID618316Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID218502Compound was tested for antiviral activity against the Vero cells infected with HSV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID618318Antiviral activity against 100 TCID50 wild type HIV1 LAI infected in human PBMC assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID734075Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg production2013European journal of medicinal chemistry, Apr, Volume: 62Anti-hepatitis B virus and anti-cancer activities of novel isoflavone analogs.
AID104764Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID275090Cytotoxicity against MAGI-CCR5 cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID618313Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID392509Antiviral activity against Hepatitis B virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID95008Antiviral activity against KOS strain of HSV-1 in E6SM cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID14006Bioavailability in rat of PMEA prodrug1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
AID446161Cytotoxicity against human HepG2(2.2.15) cells2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.
AID45385Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID678820TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Molecular pharmacology, Sep, Volume: 56, Issue:3
The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.
AID374193Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID63923Inhibitory activity against herpes simplex virus type 1 (HSV-1) KOS strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID1636539Oral bioavailability in rat at 30 mg/kg, administered through gastric intubation by HPLC analysis2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID65704Inhibition of thymidine kinase deficient Herpes simplex virus-1 VMW 1837 strain induced cytopathicity in E6SM cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID218248Evaluated for the antiviral activity against Vero cells by proliferation assays (in uninfected cells)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
AID157046Maximum velocity constant of the rate of phosphorylation was determined against PRPP synthetase2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID324764Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID83102Inhibition of cytopathogenicity against human HIV-1(IIIB) in MT-4 cells2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID611766Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID625939Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID106397Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-1 TK-(B2006) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID365170Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID626000Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant to EC90 for wild type Hepatitis B virus2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID83508Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) OKA strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID592792Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID618448Antiviral activity against TK-deficient and ACR-resistant Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID275078Stability in pH 5.2 buffer at 37 degC after 72 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID392512Antiviral activity against Herpes simplex virus 22009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID45994Cytotoxicity against CEM (human lymphoblastic leukemia) cells in vitro.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID618430Antiviral activity against HIV1 clade F isolate 2338 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID106405Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK-(YS/R) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID84430Inhibitory effect on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 250 mk/kg/day2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID1126840Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID106402Compound was tested in vitro for Minimum inhibitory concentration required to reduce VV induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID678842TP_TRANSPORTER: uptake in OCT3-expressing HEK293 cells1998Nature neuroscience, Sep, Volume: 1, Issue:5
Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.
AID3059Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID1126844Antiproliferative activity against human C33A cells after 72 hrs by flow cytometric analysis2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID618327Antiviral activity against HIV1 clade D isolate 1649 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID83512Inhibition of varicella zoster virus thymidine kinase (VZV TK+) YS/R strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID611627Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID275079Stability in pH 7.4 buffer at 37 degC after 72 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID365171Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID257122Cytotoxicity against CEM/O cells2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach.
AID310047Therapeutic index, Ratio of TC50 for human HepG2 cells to IC50 for HBV-infected human HepG2 cells2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID392514Antiviral activity against HIV22009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID618517Cytotoxicity against human HuH7 cells2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1578796Antimalarial activity against synchronized Plasmodium falciparum K1 ring form infected in human erythrocytes assessed as reduction in parasite growth after 72 hrs by Hoechst 33258 staining based fluorescence assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID23275Partition coefficient (logP)1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID611621Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID91036Cytotoxic concentration of compound required for 50% extinction of HuH-6 cells2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents.
AID365175Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID1126834Antiviral activity against Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID611629Antiviral activity against VSV infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID105857Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID1383890Antiviral activity against HIV12018European journal of medicinal chemistry, Apr-25, Volume: 150Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?
AID392511Antiviral activity against Herpes simplex virus 12009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID734079Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg production after 9 days by ELISA2013European journal of medicinal chemistry, Apr, Volume: 62Anti-hepatitis B virus and anti-cancer activities of novel isoflavone analogs.
AID405582Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID520604Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID446163Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.
AID235561Selectivity Index is the ratio of the TC50 to EC501992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Synthesis and antiviral activity of methyl derivatives of 9-[2-(phosphonomethoxy)ethyl]guanine.
AID374198Antiviral activity against Camelpox virus CML1 infected in human PHK assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID84424Inhibitory effect on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 250 mk/kg/day2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID1126839Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID520606Selectivity index, ratio of CC50 for human WI38 cells to EC50 for BK polyomavirus ATCC VR8372008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID611761Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID374196Selectivity index, ratio of CC50 for HEL299 cells to EC50 for Camelpox virus CML1 infected in HEL299 cells2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374203Cytotoxicity against HEL299 cells assessed as minimum cytotoxic concentration required for alteration in cell morphology after 4 days by microscopy2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID612651Activity of recombinant human ADAL1 expressed in Escherichia coli by UV-spectrophotometry2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N(6)- or O(6)-substituted purine or 2-aminopurine nucleoside monophosphates.
AID106403Compound was tested in vitro for Minimum inhibitory concentration required to reduce VZV TK+(OKA) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID446158Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg level after 9 days by ELISA2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.
AID618447Antiviral activity against Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID72409Antiviral activity against G strain of HSV-2 in E6SM cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID10054Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID611763Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID410760Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID324766Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID324761Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus PTA2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID618433Antiviral activity against Hepatitis B virus infected in human HepAD38 cells assessed as reduction in viral DNA level after 6 days by real time quantitative PCR analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID446162Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.
AID734078Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg production after 9 days by ELISA2013European journal of medicinal chemistry, Apr, Volume: 62Anti-hepatitis B virus and anti-cancer activities of novel isoflavone analogs.
AID1192805Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for decrease in hepatitis B viral HBeAg secretion in human HepG2.2.15 cells2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID544650Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID324768Selectivity index, ratio of CC50 for african green monkey BSC1 cells ot EC50 for Simian virus 40 A28952007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID83506Inhibitory activity against cytomegalovirus (CMV) Davis strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID618324Antiviral activity against HIV1 clade B isolate 1722 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1126835Antiviral activity against Herpes simplex virus G infected in HEL cells assessed as inhibition of virus-induced cytopathicity2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID611770Cytotoxicity against dog MDCK cells assessed as alteration of cell morphology after 3 days by microscopy2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID374195Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID1126831Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID44141Inhibition of moloney sarcoma virus (MSV) induced cytopathicity in C3H/3T3 embryo fibroblast cells2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID307877Selectivity index, ratio of CC50 for HepG2.2.15 cells to IC50 for HBV
AID625935Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID275065Antiviral activity against HIV1 in MAGI-CCR5 cells2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1192807Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as viral surface antigen HBsAg level after 9 days by ELISA (Rvb = 721 +/- 32 pg/ml)2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID106401Compound was tested in vitro for Minimum inhibitory concentration required to reduce MSV induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID268268Cytotoxicity against HepG2.2.15 cells2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives.
AID410757Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID105853Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID324767Cytotoxicity against african green monkey BSC1 cells2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID307875Inhibition of cytoplasmic HBV DNA synthesis in HepG2.2.15 cells after 8 days
AID592797Cytotoxicity against human CEM cells assessed as minimum concentration required for morphological alteration by microscopic analysis2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID79635Concentration required to inhibit 50% of cytoplasmic HBV-DNA synthesis2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents.
AID83717Evaluated for the antiviral activity against Herpes simplex virus type 1 (HSV-1) strain BWS by the plaque reduction assay1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
AID611774Antiviral activity against HIV 1 LAI infected in MT2 cells2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID310043Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID324756Antiviral activity against Murine polyomavirus PTA in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID47283Cellular toxic effect was determined in CEM cells2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID79966Evaluated for the antiviral activity against Human cytomegalovirus (HCMV) strain AD-169 by the plaque reduction assay1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
AID609586Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopy2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity.
AID374200Cytotoxicity against human PHK after 4 days by Z1 Coulter counting analysis2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID611760Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID618326Antiviral activity against HIV1 clade C isolate 4110 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID216016Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
AID84951Evaluated for the antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G by the plaque reduction assay1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
AID1126838Cytotoxicity against HEL cells assessed as change in cellular morphology by microscopic analysis2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID218503Compound was tested for antiviral activity against the Vero cells infected with HSV-21996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID410758Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID611771Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID446164Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID611618Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID142453Antiviral activity against murine sarcoma virus2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID734073Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication2013European journal of medicinal chemistry, Apr, Volume: 62Anti-hepatitis B virus and anti-cancer activities of novel isoflavone analogs.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1126836Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID84429Inhibitory effect on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 150 mk/kg/day2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID544649Activity of human OAT3 transfected in BHK-21 cells2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID611757Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID84428Inhibitory effect on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 100 mk/kg/day2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID392537Antiviral activity against Varicella zoster virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID618322Antiviral activity against HIV1 clade B isolate 2101 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID86374Compound tested for anti-HBV (hepatitis B virus) activity in HepG2 2.2.15 cell line2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent.
AID47262In vitro antiviral activity against HIV-1 in CEM cells2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID625999Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Sout2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1192808Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as viral HBcAg level after 9 days by ELISA (Rvb = 14.16 +/- 1.92 ng/ml)2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID55965Antiviral activity against Davis strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID611616Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID626004Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID544660Drug uptake in human kidney cortex at 5 uM by liquid scintillation counting in presence of 500 uM of probenecid2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID520605Cytotoxicity against human WI38 cells by neutral red assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID344318Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Anti-retroviral and cytostatic activity of 2',3'-dideoxyribonucleoside 3'-disulfides.
AID105555In vitro antiviral activity against HIV-1 in MT-4 cells2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID1126829Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID410759Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID410756Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID611772Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID82116Antiviral activity against HIV-1 was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
AID47260In vitro anti -HIV activity tested against CEM cells infected with HIV by XTT assay1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Synthesis and antiviral activity of methyl derivatives of 9-[2-(phosphonomethoxy)ethyl]guanine.
AID106724Inhibition of antiviral activity against moloney murine sarcoma virus(MSV)in CEM cells in cell protection assay2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID324758Antiviral activity against Murine polyomavirus LID1 ATCC VR-252 in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID106406Compound was tested in vitro for minimum inhibitory concentration required to reduce HSV-1(KOS) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID14005Oral bioavailability of compound in rat1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
AID257121Antiviral potency against HIV2 in CEM/O cells2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach.
AID275085Stability in CEM-SS cell extracts2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID82134Antiviral activity against HIV-1 (IIIB) in CEM (human leukemia) cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID592793Antiviral against Moloney murine sarcoma virus infected in mouse C3H/3T3 cells assessed as inhibition of virus-induced cell transformation after 6 days post infection by microscopic analysis2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID365169Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625941Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID47458Evaluated for the anticellular activity against CEM cells by dye-exclusion method1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
AID611620Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID275082Stability in pH 11.5 buffer at 37 degC after 72 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID47618Toxicity in vitro against CEM cells by XTT assay1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Synthesis and antiviral activity of methyl derivatives of 9-[2-(phosphonomethoxy)ethyl]guanine.
AID626002Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hybri2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID275084Stability in culture medium (RPMI+FBS)2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID446160Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication after 9 days by PCR2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID680354TP_TRANSPORTER: efflux in MRP5-expressing MDCKII cells2000Proceedings of the National Academy of Sciences of the United States of America, Jun-20, Volume: 97, Issue:13
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID365173Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID611769Cytotoxicity against african green monkey Vero cells assessed as alteration of cell morphology after 3 days by microscopy2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID625998Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID81790Evaluated for the antiretroviral activity against Human immunodeficiency virus type 11990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
AID592796Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID618321Antiviral activity against HIV1 clade A isolate 4113 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID618323Antiviral activity against HIV1 clade B isolate 2056 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID611615Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID83504Inhibitory activity against cytomegalovirus (CMV) AD 169 strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID307876Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay
AID679657TP_TRANSPORTER: efflux in MRP8-1-expressing LLC-PK1 cells2003The Journal of biological chemistry, Aug-08, Volume: 278, Issue:32
MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine.
AID86371Compound tested for anti-HBV (hepatitis B virus) activity in HepG2 2.2.15 cell line2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent.
AID618509Cytotoxicity against human HEL cells assessed as alteration in cellular morphology by microscopic analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID84423Inhibitory effect on HSV-1 induced mortality in NMRI mice upon (ip) administration at a dose of 150 mk/kg/day2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID1363957Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID106399Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-2(G) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID625940Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant to EC90 for wild type Hepatitis B virus2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID211497In vitro cytotoxic concentration against MT-4 cells2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID392513Antiviral activity against HIV12009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID544667Activity of human OAT3 transfected in BHK-21 cells measured per 10'6 cells2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID147626Antiviral activity against OKA strain of VZV in HEL (human erythroleukemia) cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID680358TP_TRANSPORTER: efflux in CEM-r1 cells1999Nature medicine, Sep, Volume: 5, Issue:9
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.
AID83515Compound was evaluated for inhibitory activity against varicella zoster virus thymidine kinase (VZV TK-) 07/1 strain; NA=not active1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID611759Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID734074Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg production2013European journal of medicinal chemistry, Apr, Volume: 62Anti-hepatitis B virus and anti-cancer activities of novel isoflavone analogs.
AID365172Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID611617Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID324765Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID106394Compound was tested in vitro for Minimum inhibitory concentration required to reduce CMV(Davis) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID324762Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus 2PTA22007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID63933Inhibitory activity against herpes simplex virus type 2 (HSV-2) G strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID618328Antiviral activity against HIV1 clade A/E isolate 2165 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID275077Stability in pH 1.2 buffer at 37 degC after 72 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID65703Inhibition of Herpes simplex virus-2 (G strain) induced cytopathicity in E6SM cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID63927Inhibition of herpes simplex virus type 1 thymidine kinase (HSV-1 TK-) B2006 strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID33824Michaelis rate constant is determined by the Lineweaver and Burk method against adenosine deaminase2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
AID324763Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus LID12007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID324755Antiviral activity against Murine polyomavirus MN/RDE Toronto in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID65702Inhibition of Herpes simplex virus-1, KOS strain induced cytopathicity in E6SM cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID679147TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Molecular pharmacology, Sep, Volume: 56, Issue:3
The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.
AID618314Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID324760Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus MN/RDE Toronto2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID410755Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID611764Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID611619Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID625938Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID392515Antiviral activity against Human cytomegalovirus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID544648Activity of human OAT1 transfected in CHO cells2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID625933Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hybridization assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID544651Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID72410Antiviral activity against vaccinia virus in HEL (human erythroleukemia) cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID106400Compound was tested in vitro for Minimum inhibitory concentration required to reduce HSV-2(ROD) induced cytopathicity in Human MT-4 cells1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.
AID1192803Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for decrease in hepatitis B viral surface antigen HBsAg secretion in human HepG2.2.15 cells2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID82694Inhibition of Thymidine kinase deficient (TK-) Varicella-Zoster virus (VZV) 07/1 strain induced cytopathicity n HEL cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID63929Inhibitory activity against herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) VMW 1837 strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID365174Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID63937Inhibitory activity against vaccinia virus (VV)1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID611758Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID83255Antiviral activity against HIV-2 (ROD) in CEM (human leukemia) cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID1126832Cytotoxicity against human CEM cells2014European journal of medicinal chemistry, May-06, Volume: 78PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID592791Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID275080Stability in pH 8.1 buffer at 37 degC after 72 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1186718Ratio of Kcat to Km for recombinant AK2 (unknown origin)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID618449Antiviral activity against Herpes simplex virus type 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID105133Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
AID618431Antiviral activity against HIV1 clade G isolate 3187 infected in human H9 cells assessed as inhibition of viral replication2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID46194Inhibition of Human immunodeficiency virus (HIV) -1 III B strain induced cytopathicity in CEM cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID275083Stability in RPMI-1640 medium2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID544652Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1186717Ratio of Kcat to Km for recombinant AK1 (unknown origin)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID14004Oral bioavailability of compound in monkey1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
AID257120Antiviral potency against HIV1 in CEM/O cells2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach.
AID211496In vitro cytotoxic concentration against CEM cells2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID1363962Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID611628Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID1383901Antiviral activity against HBV2018European journal of medicinal chemistry, Apr-25, Volume: 150Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?
AID611765Antiviral activity against Feline coronavirus infected in CRFK cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID625936Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID618434Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID625996Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID734076Cytotoxicity against human HepG2(2.2.15) cells compound treated for 48 hrs followed by incubation for 9 days by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Anti-hepatitis B virus and anti-cancer activities of novel isoflavone analogs.
AID163318Evaluated for the antiretroviral activity against Rauscher murine leukemia virus (R-MuLV)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.
AID324770Selectivity index, ratio of CC50 for african green monkey BSC1 cells ot EC50 for Simian virus 40 PML2 DAR2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID553332Displacement of Mant-ATP from human recombinant UCK by fluorescence competition assay2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID82697Inhibition of Varicella-Zoster virus (VZV) YS strain induced cytopathicity in HEL cell line2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,006)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (0.70)18.7374
1990's133 (13.22)18.2507
2000's383 (38.07)29.6817
2010's458 (45.53)24.3611
2020's25 (2.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.14 (24.57)
Research Supply Index7.06 (2.92)
Research Growth Index6.08 (4.65)
Search Engine Demand Index88.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials116 (11.02%)5.53%
Reviews0 (0.00%)6.00%
Reviews161 (15.29%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies90 (8.55%)4.05%
Observational0 (0.00%)0.25%
Observational5 (0.47%)0.25%
Other5 (100.00%)84.16%
Other681 (64.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (112)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label Study of Adefovir Dipivoxil for the Treatment of Patients With Chronic Hepatitis B Related Advanced Fibrosis or Cirrhosis. [NCT00347009]Phase 4155 participants (Actual)Interventional2005-05-31Completed
An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B Associated Hepatocellular Carcinoma [NCT01263002]Phase 433 participants (Anticipated)Interventional2010-06-30Completed
A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of Lamivudine and Adefovir Dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg) [NCT01353742]Phase 140 participants (Actual)Interventional2011-02-21Completed
A Multi-center, Randomized, Double-blind, Positive-control, Phase III Trial of the Efficacy and Safety of Clevudine [NCT01192854]Phase 3288 participants (Actual)Interventional2010-02-28Completed
Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Lamivudine Plus Adefovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir Combination Therapy - Multicenter Randomiz [NCT03236584]Phase 376 participants (Actual)Interventional2015-09-01Active, not recruiting
Protocol Title: A Phase II Open-labeled Study to Determine the Safety and Preliminary Efficacy of Interferon-gamma 1b (IFN-γ 1b) in Patients With Chronic Hepatitis B Who Are HBV DNA Positive [NCT00753467]Phase 230 participants (Anticipated)Interventional2008-09-30Not yet recruiting
A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) [NCT02327416]Phase 3300 participants (Anticipated)Interventional2014-10-31Recruiting
A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy [NCT01341743]Phase 4360 participants (Anticipated)Interventional2010-12-31Active, not recruiting
Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B [NCT02075294]242 participants (Actual)Observational2010-01-31Completed
An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B [NCT01264354]Phase 460 participants (Anticipated)Interventional2010-03-31Completed
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2 to Less Than 18) With Chronic Hepatitis B [NCT00095121]Phase 3173 participants (Actual)Interventional2004-06-30Completed
An Open-label, Multicenter, Randomized Study of Combination Therapy With Oral LDT600 (Telbivudine) Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant [NCT00376259]Phase 343 participants (Actual)Interventional2007-01-31Terminated(stopped due to The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA))
A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection [NCT03253250]Phase 4432 participants (Anticipated)Interventional2017-09-01Recruiting
A Randomized, Open Label Study to Compare the Effect of Combination Treatment With PEGASYS + Adefovir Dipivoxil Versus PEGASYS Monotherapy on HBV-DNA and ALT Levels in Patients With HBeAg-negative, Chronic Hepatitis B.' [NCT00661076]Phase 310 participants (Actual)Interventional2008-08-31Completed
Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection [NCT00096785]Phase 369 participants (Actual)Interventional2004-12-31Completed
Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation [NCT00065507]Phase 3195 participants (Actual)Interventional2003-08-31Completed
A Prospective, Randomised, Open-label, Multi-centre Study to Compare Three Chronic Hepatitis B (CHB) Treatment Strategies Over a 2year Period in Chinese HBeAg Positive CHB Patients [NCT01088009]Phase 4366 participants (Actual)Interventional2010-03-31Completed
[NCT01139203]300 participants (Anticipated)Interventional2009-08-31Recruiting
Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS) [NCT01373684]Phase 490 participants (Actual)Interventional2012-05-25Completed
An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B [NCT01264133]Phase 4200 participants (Anticipated)Interventional2009-09-30Terminated
Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir [NCT01023217]Phase 490 participants (Actual)Interventional2009-11-30Completed
A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B [NCT00672867]Phase 3102 participants (Anticipated)Interventional2007-12-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Adefovir Dipivoxil as Intensification Therapy in Combination With Highly Active Antiretroviral Therapy (HAART) in HIV Infected Patients With HIV-1 RNA > 50 and [NCT00002426]390 participants InterventionalCompleted
Combination Therapy With TACE and Adefovir Compared With TACE Alone for HBV-related Unresectable Hepatocellular Carcinoma [NCT00960518]Phase 2216 participants (Anticipated)Interventional2009-08-31Recruiting
A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects [NCT00986778]Phase 40 participants (Actual)Interventional2009-12-31Withdrawn(stopped due to Business Objectives Changed)
"A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Response-Guided-Therapy (RGT) Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients" [NCT02560649]Phase 4324 participants (Anticipated)Interventional2015-05-31Active, not recruiting
A Study on Optimizing the Treatment in HBeAg Positive CHB Patients With Response Guide Treatment (RGT) Method. [NCT01086085]Phase 4265 participants (Actual)Interventional2010-04-30Completed
Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase Ⅲ Trial [NCT02366247]Phase 3463 participants (Actual)Interventional2013-08-31Active, not recruiting
Single Centre in Vivo Cocktail Phenotyping Study on OATP1B1, OCT1/2, MATE1/2K, OAT1/3, and P-gp Drug Transporters in Healthy Volunteers [NCT02743260]Phase 424 participants (Actual)Interventional2016-04-30Completed
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS®) or Adefovir Dipivoxil (ADV) in Patients With Lamivudine-resistant HBeAg Positive Chronic Hepatitis B [NCT02598063]Phase 4255 participants (Actual)Interventional2005-10-31Completed
A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function [NCT00641082]Phase 443 participants (Actual)Interventional2008-02-29Completed
A Phase 1-2 Open-Label Study of the Pharmacokinetics and Safety of a Single Dose of Adefovir Dipivoxil in Children and Adolescents (Aged 2-17) With Chronic Hepatitis B [NCT00645294]Phase 1/Phase 247 participants (Actual)Interventional2003-02-28Completed
A Randomized Prospective Open-label Trial for Comparing Combination Therapy Peg-Interferon Alfa-2a/Adefovir Dipivoxil and Peg-Interferon Alfa-2a/Tenofovir Disoproxil Fumarate Versus no Treatment in HBeAg Negative Chronic Hepatitis B Patients With Low Vira [NCT00973219]151 participants (Actual)Interventional2009-09-30Completed
A Comparative Study of the Week 12 Antiviral Efficacy and Safety of Switching to Entecavir vs. Continuing Adefovir Treatment in Adults With Chronic Hepatitis B and Suboptimal Response to Adefovir [NCT00718887]Phase 4228 participants (Actual)Interventional2008-07-31Completed
A Multicenter, Randomized, Controlled Tial of Combination Therapy for Lamivudine-resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir [NCT00798460]Phase 430 participants (Actual)Interventional2008-12-31Terminated(stopped due to could not enroll patients)
Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) [NCT02826070]Phase 4130 participants (Actual)Interventional2015-04-30Active, not recruiting
A Phase IV, Open Label, Single Arm, Multicenter, Extension Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814 [NCT00403585]Phase 480 participants (Actual)Interventional2006-07-31Completed
A 26 Week Randomized, Open Label, Multi-center Study of the Efficacy and Safety of Telbivudine 600 mg Once Daily Versus Adefovir Dipivoxil 10mg Once Daily in Subjects With Compensated Chronic Hepatitis B and Sub-optimal Response to at Least 48 Weeks of Ad [NCT00606099]Phase 40 participants (Actual)Interventional2007-11-30Withdrawn(stopped due to study was cancelled)
An Open-Label, Randomized, Comparative Study With PegIntron vs. Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan [NCT00371761]Phase 325 participants (Actual)Interventional2006-09-30Completed
A 2-year Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B [NCT00324961]Phase 4533 participants (Actual)Interventional2006-01-31Completed
Activity of the Soft Gelatin Capsule of Saquinavir (SQVsgc) in Combination With Ritonavir or Nelfinavir and Combinations of Delavirdine and/or Adefovir Dipivoxil in HIV-Infected Subjects With Prior Indinavir Use and Viral Loads From 2,000 to 200,000 Copie [NCT00000892]300 participants InterventionalCompleted
Adefovir Dipivoxil for the Treatment of Hepatitis B in Human Immunodeficiency Virus Infected Patients With Decompensated Hepatitis B Liver Disease and a Hepatitis B Viral Load of at Least 1.0 X 10(6) (Copies/mL) Despite 52 Weeks of Lamivudine Therapy [NCT00013702]Phase 230 participants Interventional2001-03-31Completed
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection. [NCT00810524]Phase 4600 participants (Anticipated)Interventional2007-01-31Recruiting
Phase III Study of Adefovir Dipivoxil Tablets in Patients With Compensated Chronic Hepatitis B -Comparative Study Against Lamivudine- [NCT00316719]Phase 3105 participants (Actual)Interventional2006-01-31Completed
A 48-week Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B [NCT00441974]Phase 41,470 participants (Actual)Interventional2006-12-31Completed
A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-resistant Chronic Hepatitis B Subjects: The DEFINE Study [NCT00410202]Phase 3629 participants (Actual)Interventional2008-03-31Completed
A Randomized, Open-label, Three-sequence, Three-period, Three-treatment Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects [NCT01581242]Phase 142 participants (Anticipated)Interventional2012-04-30Completed
Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201 [NCT00230490]Phase 2150 participants Interventional2005-06-30Terminated(stopped due to Adverse findings from nonclinical carcinogenicity studies.)
Comparison of the Virologic Efficacy of Nelfinavir and/or DMP 266 (Efavirenz, EFV) in Combination With One or Two New Nucleoside Analogs in Nucleoside Experienced Subjects: A Roll-Over Study to ACTG 302/303 [NCT00001087]Phase 2300 participants InterventionalCompleted
Effect of Age on the Renal Clearance of Adefovir [NCT00187746]Phase 40 participants (Actual)Interventional2005-08-31Withdrawn(stopped due to Budget exceeded for project.)
A Multi-Center Phase 2, Open-Label Study to Evaluate the Pharmacokinetics of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil 10 mg to Patients Post-Liver Transplantation [NCT00644761]Phase 216 participants (Actual)Interventional2004-02-29Completed
Prospective Exploratory Study to Describe in CHB naïve and Non-naïve Patients, Hepatitis B Virus (HBV) Kinetics During the First 24 Weeks of Treatment With Telbivudine [NCT00640588]Phase 330 participants (Actual)Interventional2008-03-31Completed
A Prospective, Randomized, Trial to Investigate the Effect of Continued Adefovir Versus Combination Regimens of Telbivudine Plus Adefovir, and Telbivudine Plus Tenofovir in Patients With Chronic Hepatitis B and Suboptimal Viral Suppression (PROACTIV Study [NCT00409019]Phase 40 participants (Actual)InterventionalWithdrawn(stopped due to Study cancelled: Withdrawn before enrollment of any participants)
Drug Use Investigation for HEPSERA (Adefovir) Tablet [NCT01863589]436 participants (Actual)Observational2005-02-28Completed
A Phase I/II Study of Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) and Placebo in HIV-Infected Patients [NCT00002346]Phase 136 participants InterventionalCompleted
Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment [NCT01491295]Phase 4160 participants (Anticipated)Interventional2012-09-30Recruiting
A Randomization Trial of Adjuvant Lamivudine/ Adefovir Dipivoxil Against Recurrence in Post-operative HBV-related Hepatocellular Carcinoma [NCT00455091]117 participants (Actual)Observational2007-05-31Terminated(stopped due to No cases enrollment)
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Positive Chronic Hepatitis Due to Hepati [NCT00496002]Phase 30 participants Interventional2007-08-31Terminated(stopped due to The study was terminated in the interest of patient safety.)
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepati [NCT00496158]Phase 30 participants Interventional2007-08-31Terminated(stopped due to The study was terminated in the interest of patient safety.)
A Single Center, Randomized, Open-label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-week Period [NCT00513968]Phase 127 participants (Actual)Interventional2007-07-31Completed
Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B [NCT00531167]Phase 4219 participants (Actual)Interventional2007-04-30Completed
A Phase 1 Open-label, Three Arm Study in Healthy Adult Volunteers to Assess Vadadustat as a Perpetrator in Drug-Drug-Interactions With Digoxin, Adefovir and Furosemide [NCT03801759]Phase 162 participants (Actual)Interventional2018-07-20Completed
A Phase II, Randomized Trial of Amprenavir as Part of Dual Protease Inhibitor Regimens (Placebo-Controlled) in Combination With Abacavir, Efavirenz, and Adefovir Dipivoxil Versus Amprenavir Alone in HIV-Infected Subjects With Prior Exposure to Approved Pr [NCT00000912]Phase 2475 participants InterventionalCompleted
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (R [NCT00002184]Phase 2120 participants InterventionalCompleted
Multi-Center, Open-Label Study of the Effect of Indinavir, Efavirenz, and Adefovir Dipivoxil Combination Therapy in Patients Who Have Failed Nelfinavir [NCT00002220]Phase 3120 participants InterventionalCompleted
Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B [NCT00230503]Phase 2220 participants Interventional2004-06-30Completed
A Multi-Center Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Varying Degrees of Renal Impairment [NCT00071201]Phase 348 participants Interventional2003-06-30Completed
A Randomized,Double-blind,Double-dummy,Multiple-dose Parallel Control,Multiple Centers Study to Assess the Safety and Dose-range of Metacavir Enteric-coated Capsules for Patients With Chronic Hepatitis B [NCT02965859]Phase 2180 participants (Anticipated)Interventional2012-12-31Recruiting
A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B [NCT00115245]Phase 30 participants Interventional2004-11-30Completed
A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy [NCT00489151]70 participants (Anticipated)Interventional2005-06-30Recruiting
A Randomized, Open-label Study of the Effect of Peginterferon Alfa-2a (40KD)(PEGASYS) in Combination With Adefovir or Entecavir on HBeAg Seroconversion in Patients With HBeAg Positive Chronic Hepatitis B [NCT00922207]Phase 4280 participants (Actual)Interventional2010-05-07Completed
A Multi-centre, Double Blind, Double Dummy, Randomised, Controlled Study to Evaluate the Efficacy and Safety of TDF 300mg Once Daily (QD) Versus Adefovir Dipivoxil (ADV) 10mg QD in Chinese Subjects With CHB [NCT01300234]Phase 3512 participants (Actual)Interventional2011-03-30Completed
A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy [NCT01521975]Phase 4360 participants (Actual)Interventional2011-01-01Completed
Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance [NCT01546116]Phase 420 participants (Actual)Interventional2010-02-28Completed
A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV [NCT00033163]Phase 290 participants InterventionalCompleted
A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options [NCT00042393]0 participants Expanded AccessApproved for marketing
Studies of the Addition of Adefovir Dipivoxil to Lamivudine for the Treatment of Chronic Hepatitis B: A Randomized, Double-Blind, Placebo Controlled Study in HIV-Infected Patients and an Open-Label Study in HIV-Negative Subjects [NCT00023153]Phase 3100 participants Interventional2001-08-31Completed
A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease [NCT00051077]Phase 20 participants (Actual)InterventionalWithdrawn
Efficacy of Adefovir Dipivoxil Versus Adefovir Dipivoxil Plus Lamivudine for the Treatment of Chronic Hepatitis B in Patients With Normal Baseline ALT [NCT00230477]Phase 419 participants (Actual)Interventional2003-04-30Completed
[NCT01693679]Phase 4120 participants (Anticipated)Interventional2012-09-30Active, not recruiting
Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA. [NCT01732367]Phase 4171 participants (Actual)Interventional2012-11-30Completed
Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study [NCT01804387]Phase 460 participants (Anticipated)Interventional2011-05-31Recruiting
A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study [NCT01829685]Phase 4360 participants (Anticipated)Interventional2013-03-31Active, not recruiting
Prevention of de Novo Hepatitis B Infection With Adefovir Dipivoxil (ADV) and Hepatitis B Vaccination in HBsAg Seronegative Recipients of Liver Grafts From Hepatitis B Core Antibody Positive (HBcAb+) Donors [NCT01146808]Phase 1/Phase 216 participants (Actual)Interventional2006-03-31Completed
A Phase IA Single Dose Pharmacokinetics and Safety Study of the Oral Antiviral Compound, 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) (Adefovir Dipivoxil) in Children With HIV-1 Infection [NCT00000843]Phase 124 participants InterventionalCompleted
A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 [NCT00000885]Phase 2440 participants InterventionalCompleted
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease. [NCT00002115]Phase 120 participants InterventionalCompleted
A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination With Zidovudine, Lamivudine, or Stavudine for the Treatment of Therapy Naive HIV-Infected Patients With CD4 Ce [NCT00002379]Phase 2100 participants InterventionalCompleted
A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients [NCT01436539]Phase 4300 participants (Anticipated)Interventional2011-09-30Not yet recruiting
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients [NCT00002128]Phase 115 participants InterventionalCompleted
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of Combination Zidovudine (AZT) and 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA; Adefovir) Treatment in HIV-Infected Patients [NCT00002326]Phase 120 participants InterventionalCompleted
A Phase I/II, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 60 Mg Daily Dose of Adefovir Dipivoxil in HIV-Infected Patients Naive to Anti-Retroviral Therapy [NCT00002206]Phase 145 participants InterventionalCompleted
A Randomized, Open-Label Expanded Access Program to Evaluate the Safety of Preveon (Adefovir Dipivoxil) at Two Dose Levels When Used in Combination With Other Antiretroviral Agents for the Treatment of Patients With HIV Infection Who Have Failed Other Ant [NCT00002398]0 participants InterventionalCompleted
Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus [NCT02482272]Phase 490 participants (Anticipated)Interventional2015-05-31Recruiting
Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B [NCT00023309]Phase 241 participants (Actual)Interventional2001-08-31Completed
Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance [NCT01595633]Phase 4124 participants (Anticipated)Interventional2012-03-31Recruiting
A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation [NCT01597934]Phase 4104 participants (Anticipated)Interventional2012-08-31Active, not recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (Bis-POM PMEA) in Prolonging Survival of HIV-Infected Individuals With a CD4+ Cell Count of <= 100/mm3 or With a CD4+ Cell Count Both > 100 an [NCT00001082]Phase 3505 participants (Actual)Interventional1996-12-31Completed
A Phase II, 48 Week, Open-Label Study Designed to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Simplified Dosing Regimen of Preveon (Adefovir Dipivoxil; bis-POM PMEA), Videx (Didanosine; ddI), Sustiva (Efavirenz; DMP-266), and Ep [NCT00002234]Phase 225 participants InterventionalCompleted
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of Novel Quadruple-Combination Therapy With Preveon (Adefovir Dipivoxil; Bis-POM PMEA), Abacavir (1592U89), Sustiva (Efavirenz; DMP-266), and Amprenavir (141 [NCT00002419]Phase 225 participants InterventionalCompleted
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3 [NCT00002161]400 participants InterventionalCompleted
A Phase I/II, Open-Label, Multi-Center Study of the Pharmacokinetics, Safety, Tolerance and Activity of Two Dose Levels of Adefovir Dipivoxil (ADF) and Nelfinavir When Added to Antiretroviral Therapy for the Treatment of HIV-Infected Pediatric Patients [NCT00002219]Phase 236 participants InterventionalActive, not recruiting
SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL) [NCT01928511]Phase 4254 participants (Actual)Interventional2014-01-31Completed
Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg) -Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase II Trial [NCT02366208]Phase 2116 participants (Actual)Interventional2011-05-31Completed
Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients [NCT02327689]Phase 4400 participants (Anticipated)Interventional2015-01-31Not yet recruiting
A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study [NCT01834508]Phase 4600 participants (Anticipated)Interventional2013-03-31Active, not recruiting
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis [NCT01720238]621 participants (Actual)Observational2012-03-31Active, not recruiting
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC [NCT03084250]Phase 4150 participants (Anticipated)Interventional2017-03-10Active, not recruiting
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Versus Adefovir Added to Continuing Lamivudine in Adults With Lamivudine- Resistant Chronic Hepatitis B Virus Infection [NCT00605384]Phase 34 participants (Actual)Interventional2008-08-31Terminated(stopped due to Business Objectives Have Changed)
Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial [NCT01799486]Phase 4300 participants (Anticipated)Interventional2013-02-28Active, not recruiting
A Single Center Open-Label, Randomized Study Comparing the Safety of Immediately Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir for 12 Weeks Before Instituting Adefovir Dipivoxil Monotherapy in Patients With Chr [NCT00307242]Phase 440 participants (Actual)Interventional2005-06-17Completed
A Post-marketing Surveillance to Monitor the Safety of HEPSERA(Adefovir Dipivoxil 10mg) Adminstered in Korean Subjects According to the Prescribing Information [NCT01329419]4,393 participants (Actual)Observational2004-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00023309 (5) [back to overview]Maintained Combined Response (Virological, Biochemical and Histological Response).
NCT00023309 (5) [back to overview]Histological Response
NCT00023309 (5) [back to overview]HBeAg Loss at Week 196
NCT00023309 (5) [back to overview]Biological Response
NCT00023309 (5) [back to overview]Virological Response
NCT00065507 (26) [back to overview]Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48
NCT00065507 (26) [back to overview]Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up
NCT00065507 (26) [back to overview]Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment
NCT00065507 (26) [back to overview]Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48
NCT00065507 (26) [back to overview]Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48
NCT00065507 (26) [back to overview]Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period
NCT00065507 (26) [back to overview]Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data
NCT00065507 (26) [back to overview]Change From Baseline in Platelet Count Through Week 48
NCT00065507 (26) [back to overview]Participants Achieving Albumin Normalization Through Week 48
NCT00065507 (26) [back to overview]Participants Achieving Platelet Count Normalization Through Week 48
NCT00065507 (26) [back to overview]Participants Achieving Prothrombin Time Normalization Through Week 48
NCT00065507 (26) [back to overview]Participants Achieving Total Bilirubin Normalization Through Week 48
NCT00065507 (26) [back to overview]Change From Baseline in HBV DNA by PCR at Week 48
NCT00065507 (26) [back to overview]Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24
NCT00065507 (26) [back to overview]Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24
NCT00065507 (26) [back to overview]Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48
NCT00065507 (26) [back to overview]>=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48
NCT00065507 (26) [back to overview]Change From Baseline in Albumin Through Week 48
NCT00065507 (26) [back to overview]Change From Baseline in Child-Pugh Score Through Week 48
NCT00065507 (26) [back to overview]Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL
NCT00065507 (26) [back to overview]Improvement or No Worsening in MELD Score Through Week 48
NCT00065507 (26) [back to overview]Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48
NCT00065507 (26) [back to overview]Mean Change From Baseline in Prothrombin Time Through Week 48
NCT00065507 (26) [back to overview]Mean Change From Baseline in Total Bilirubin Through Week 48
NCT00065507 (26) [back to overview]Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48
NCT00065507 (26) [back to overview]Number of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48
NCT00095121 (22) [back to overview]Percentage of Participants With Normal ALT at ADV Week 192 (Missing = Failure)
NCT00095121 (22) [back to overview]Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 192 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)
NCT00095121 (22) [back to overview]Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 240 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)
NCT00095121 (22) [back to overview]Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss or Seroconversion by End of Blinded Treatment (Study Week 48; Randomized and Treated Analysis Set)
NCT00095121 (22) [back to overview]Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal Alanine Aminotransferase (ALT) at Week 48 (Missing = Failure)
NCT00095121 (22) [back to overview]Adefovir (ADV) Baseline Serum HBV DNA
NCT00095121 (22) [back to overview]ADV Baseline ALT
NCT00095121 (22) [back to overview]Change From ADV Baseline to ADV Week 192 for ALT
NCT00095121 (22) [back to overview]Change From ADV Baseline to ADV Week 192 for Serum HBV DNA
NCT00095121 (22) [back to overview]Change From ADV Baseline to ADV Week 240 for ALT
NCT00095121 (22) [back to overview]Change From ADV Baseline to ADV Week 240 for Serum HBV DNA
NCT00095121 (22) [back to overview]Percentage of Participants With Durable HBeAg Seroconversion
NCT00095121 (22) [back to overview]Percentage of Participants With Normal ALT at Adefovir Baseline (Missing = Failure)
NCT00095121 (22) [back to overview]Percentage of Participants With Normal ALT at ADV Week 240 (Missing = Failure)
NCT00095121 (22) [back to overview]Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance) for Subjects Who Received Combination ADV + Lamivudine Therapy
NCT00095121 (22) [back to overview]Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment - Missing = Failure) (ADV Week 192)
NCT00095121 (22) [back to overview]Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)
NCT00095121 (22) [back to overview]Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)
NCT00095121 (22) [back to overview]Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)
NCT00095121 (22) [back to overview]Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 192)
NCT00095121 (22) [back to overview]Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)
NCT00095121 (22) [back to overview]Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance)
NCT00096785 (10) [back to overview]HBV DNA Viral Kinetics - Spline Model
NCT00096785 (10) [back to overview]HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections
NCT00096785 (10) [back to overview]HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate
NCT00096785 (10) [back to overview]Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs
NCT00096785 (10) [back to overview]Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths
NCT00096785 (10) [back to overview]Alanine Aminotransferase (ALT) Normalization
NCT00096785 (10) [back to overview]Change From Baseline in HBV DNA by PCR Assay at Week 48
NCT00096785 (10) [back to overview]Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12
NCT00096785 (10) [back to overview]HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus
NCT00096785 (10) [back to overview]Viral Load Undetectable (HBV DNA <300 Copies/mL)
NCT00316719 (10) [back to overview]Percentage of Participants With HBV DNA Loss (<400 Copies/mL) at Week 52
NCT00316719 (10) [back to overview]Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 52
NCT00316719 (10) [back to overview]Percentage of Participants With Hepatitis B e Antigen/Antibody (HBeAg/Ab) Seroconversion at Week 52
NCT00316719 (10) [back to overview]Percentage of Participants With Hepatitis B s Antigen (HBsAg) Loss at Week 52
NCT00316719 (10) [back to overview]Percentage of Participants With Hepatitis B s Antigen/ Antibody (HBsAg/Ab) Seroconversion at Week 52
NCT00316719 (10) [back to overview]Rate of Emergence of Resistant Virus at Week 52
NCT00316719 (10) [back to overview]Mean Alanine Aminotransferase (ALT) Level at Week 52
NCT00316719 (10) [back to overview]Mean Change From Baseline in Hepatitis B Virus (HBV) DNA at Week 52
NCT00316719 (10) [back to overview]Time to Onset of ALT Normalization
NCT00316719 (10) [back to overview]Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 52
NCT00324961 (10) [back to overview]Number of Participants Achieving Histological Improvement After the 104-week Treatment
NCT00324961 (10) [back to overview]Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104
NCT00324961 (10) [back to overview]Number of Participants Achieving HBV DNA ≤300 Copies/mL Over Time
NCT00324961 (10) [back to overview]Number of Participants With ADV-associated Resistance at Week 104
NCT00324961 (10) [back to overview]Number of Participants Achieving Complete Response at Week 104
NCT00324961 (10) [back to overview]Time to Protocol-defined Complete Response Over a 104-week Treatment Period
NCT00324961 (10) [back to overview]Change From Baseline in Median Serum HBV DNA Over Time
NCT00324961 (10) [back to overview]Liver Histology Scores in HBeAg Negative Participants With Two Sequential Liver Biopsies During the Period of 104 Weeks
NCT00324961 (10) [back to overview]Number of Participants Achieving ALT Normalization at Week 104
NCT00324961 (10) [back to overview]Number of Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 104
NCT00347009 (14) [back to overview]Number of Participants With Histologic Improvement at Month 36 (Per Protocol Population)
NCT00347009 (14) [back to overview]Change From Baseline in Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants Achieving Virological Response (HBV DNA Level <= 10^3 Copies/ml) at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants Achieving Virological Response (HBV DNA Level <= 10^4 Copies/ml) at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants Who Were HBeAg Positive at Baseline, With HBeAg Seroconversion at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants Who Were HBsAg Positive at Baseline, With HBsAg Seroconversion at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants Who Were Hepatitis B Envelope Antigen (HBeAg) Positive at Baseline and Developed Undetectable Levels of HBeAg at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants Who Were Hepatitis B Surface Antigen (HBsAg) Positive at Baseline and Developed Undetectable Levels of HBsAg at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants With a Reduction From Baseline in the Child-Pugh Score by 2 Points or More at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants With Alanine Aminotransferase (ALT) Normalization at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants With Undetectable HBV DNA at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants With Virological Breakthrough at Months 12, 24, and 36
NCT00347009 (14) [back to overview]Number of Participants With Histologic Improvement at Month 36 (Intent-to-Treat Population)
NCT00347009 (14) [back to overview]Number of Participants With a Reduction From Screening of at Least 2 Points in the Knodell Necroinflammation Score at Month 36
NCT00371761 (1) [back to overview]Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response
NCT00376259 (2) [back to overview]Percentage of Participants Achieving Specified Clinical and Laboratory Safety Criteria
NCT00376259 (2) [back to overview]Change From Baseline in Mean Hepatitis B Virus (HBV) DNA Concentration
NCT00403585 (6) [back to overview]Number of Participants With HBeAg Loss, HBeAg Seroconversion, HBsAg Loss and HBsAg Seroconversion at Week 104 & 156
NCT00403585 (6) [back to overview]Hepatitis B Virus (HBV) DNA (log10 Copies/mL) Change From Baseline at Week 156 of Adefovir Therapy
NCT00403585 (6) [back to overview]Safety Assessment: Number of Participants With a Serious Adverse Event and an Adverse Event
NCT00403585 (6) [back to overview]Number of Participants Achieving ALT Normalization at Week 104 & 156
NCT00403585 (6) [back to overview]Number of Participants Achieving Virological Response at Week 104 & 156
NCT00403585 (6) [back to overview]HBV DNA Levels at Each Collection Time Point From Baseline Through Week 156
NCT00410202 (25) [back to overview]Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96
NCT00410202 (25) [back to overview]Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
NCT00410202 (25) [back to overview]Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96
NCT00410202 (25) [back to overview]Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48
NCT00410202 (25) [back to overview]Change in Mean log10 From Baseline in HBV DNA at Week 48
NCT00410202 (25) [back to overview]Cumulative Probability of Emergent Genotypic Resistance at Year 1
NCT00410202 (25) [back to overview]Cumulative Probability of Emergent Genotypic Resistance at Year 2
NCT00410202 (25) [back to overview]Number of Participants With Laboratory Abnormalities: Serum Chemistry
NCT00410202 (25) [back to overview]Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment
NCT00410202 (25) [back to overview]Percentage of Participants With HBV DNA by PCR Category at Week 48
NCT00410202 (25) [back to overview]Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)
NCT00410202 (25) [back to overview]Percentage of Participants With HBV DNA by PCR Category at Week 96
NCT00410202 (25) [back to overview]Change in Mean log10 From Baseline in HBV DNA at Week 96
NCT00410202 (25) [back to overview]Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48
NCT00410202 (25) [back to overview]Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96
NCT00410202 (25) [back to overview]Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
NCT00410202 (25) [back to overview]Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96
NCT00410202 (25) [back to overview]Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48
NCT00410202 (25) [back to overview]Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96
NCT00410202 (25) [back to overview]Number of Participants With Laboratory Abnormalities: Hematology
NCT00410202 (25) [back to overview]Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)
NCT00410202 (25) [back to overview]Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)
NCT00410202 (25) [back to overview]Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)
NCT00410202 (25) [back to overview]Percentage of Participants With HBsAg Seroconversion at Week 48
NCT00410202 (25) [back to overview]Percentage of Participants With HBsAg Seroconversion at Week 96
NCT00441974 (7) [back to overview]Number of HBeAg Positive Participants Achieving Histological Improvement at Week 48
NCT00441974 (7) [back to overview]Change From Screening in Median Serum HBV DNA at Weeks 24 and 48
NCT00441974 (7) [back to overview]Number of HBeAg Positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Week 48
NCT00441974 (7) [back to overview]Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) <1000 Copies/Milliliter at Week 48
NCT00441974 (7) [back to overview]Number of Participants With ADV-associated Resistance at Week 48
NCT00441974 (7) [back to overview]Ranked Assessment of Liver Histology in HBeAg Positive Participants From Baseline to Week 48
NCT00441974 (7) [back to overview]Number of Participants Achieving ALT (Alanine Aminotransferase) Normalization at Week 48
NCT00605384 (1) [back to overview]Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities
NCT00718887 (9) [back to overview]Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing
NCT00718887 (9) [back to overview]Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing
NCT00718887 (9) [back to overview]Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing
NCT00718887 (9) [back to overview]Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation
NCT00718887 (9) [back to overview]Number of Participants With Genotypic Resistance to Entecavir
NCT00718887 (9) [back to overview]Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion
NCT00718887 (9) [back to overview]Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)
NCT00718887 (9) [back to overview]Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results
NCT00718887 (9) [back to overview]Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion
NCT00922207 (7) [back to overview]Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment
NCT00922207 (7) [back to overview]Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
NCT00922207 (7) [back to overview]Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
NCT00922207 (7) [back to overview]Percentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive
NCT00922207 (7) [back to overview]Percentage of Participant With Normal Alanine Aminotransferase (ALT) Levels
NCT00922207 (7) [back to overview]Percentage of Participants Who Were HBeAg Negative
NCT00922207 (7) [back to overview]Percentage of Participants With Combined Response
NCT01023217 (1) [back to overview]Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)
NCT01146808 (3) [back to overview]Proportion of Patients With a Sustained Hepatitis B Surface Antibody Titer > 500 IU/mL Prior to and After Vaccination
NCT01146808 (3) [back to overview]Proportion of Patients Who Develop de Novo Hepatitis B Infection Post ADV Withdrawal, Which Will be Assessed at 6 Months Post Withdrawal
NCT01146808 (3) [back to overview]Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver
NCT01300234 (15) [back to overview]Number of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.
NCT01300234 (15) [back to overview]Number of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)
NCT01300234 (15) [back to overview]Number of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus
NCT01300234 (15) [back to overview]Number of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240
NCT01300234 (15) [back to overview]Participants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240
NCT01300234 (15) [back to overview]Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48
NCT01300234 (15) [back to overview]Number of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240
NCT01300234 (15) [back to overview]Number of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240
NCT01300234 (15) [back to overview]Number of Participants in the Indicated Category for Renal Laboratory Abnormalities
NCT01300234 (15) [back to overview]Number of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.
NCT01300234 (15) [back to overview]Number of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240
NCT01300234 (15) [back to overview]Change From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240
NCT01300234 (15) [back to overview]Number of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48
NCT01300234 (15) [back to overview]Number of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline
NCT01300234 (15) [back to overview]Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)
NCT01329419 (3) [back to overview]Number of Participants With a Serious Adverse Event
NCT01329419 (3) [back to overview]Number of Participants With an Adverse Event
NCT01329419 (3) [back to overview]Number of Participants With the Indicated Unexpected Adverse Events

Maintained Combined Response (Virological, Biochemical and Histological Response).

A maintained combined response was defined as a combination of a virological, biochemical and histological responses at weeks 48 and 192. A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (<500 copies/mL). A biochemical response was defined as a decrease in serum ALT levels into the normal range (<41 U/L). A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score. (NCT00023309)
Timeframe: 196 weeks from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir613
Lamivudine and Adefovir157

[back to top]

Histological Response

A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score. (NCT00023309)
Timeframe: week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir55
Lamivudine and Adefovir153

[back to top]

HBeAg Loss at Week 196

Loss of hepatitis B surface antigen (HBsAg) at week 196 (NCT00023309)
Timeframe: Week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir59
Lamivudine and Adefovir134

[back to top]

Biological Response

A biochemical response was defined as a decrease in serum ALT levels into the normal range (<41 U/L). (NCT00023309)
Timeframe: week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir127
Lamivudine and Adefovir211

[back to top]

Virological Response

A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (<500 copies/mL). (NCT00023309)
Timeframe: Week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir613
Lamivudine and Adefovir175

[back to top]

Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48

(NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

,
InterventionParticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 48
Adefovir (ADV) 10 mg1611162434
Entecavir (ETV) 1.0 mg32334374957

[back to top]

Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up

(NCT00065507)
Timeframe: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.

,
Interventionparticipants (Number)
Liver Transplant: YesLiver Transplant: No
Adefovir (ADV) 10 mg386
Entecavir (ETV) 1.0 mg1191

[back to top]

Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment

ALT flare=ALT > 2 x baseline and > 10 x upper limit of normal (ULN) by clinical laboratory evaluation. Table includes number of participants with selected clinical events and/or laboratory abnormalities during ALT flares. Selected clinical events during ALT flares=ascites, hepatic encephalopathy, jaundice, bacterial peritonitis. Selected Laboratory abnormalities during ALT flares=international normalized ratio > 1.5 or prothrombin time >= 1.2 x ULN and total bilirubin >2.5 mg/dL and > 1 mg/dL increase from baseline. (NCT00065507)
Timeframe: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date.

,
Interventionparticipants (Number)
ALT flaresALT flares, no clinical events/lab abnormalitiesALT flares, with clinical events/lab abnormalities
Adefovir (ADV) 10 mg101
Entecavir (ETV) 1.0 mg211

[back to top]

Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48

Number of Participants in each group with improvement in Child-Pugh score from baseline to Week 48 as measured by improvement in Child-Pugh class. Improvement in Child-Pugh Class is defined as change from B to A or C to A. Evaluable subjects are subjects with Child-Pugh Class B or C at Baseline. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). Child-Pugh class A to C employs the added score from above: 5-6=Class A; 7-9=Class B; 10-15=Class C. (NCT00065507)
Timeframe: Week 24, Week 48

,
InterventionParticipants (Number)
Week 24Week 48
Adefovir (ADV) 10 mg2229
Entecavir (ETV) 1.0 mg2535

[back to top]

Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48

Number of participants in each group with improvement or no worsening in Child-Pugh score from baseline to Week 48 as measured by improvement or no worsening in Child-Pugh score. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

,
InterventionParticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 48
Adefovir (ADV) 10 mg06762626561
Entecavir (ETV) 1.0 mg06667686661

[back to top]

Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period

Data includes type of malignant neoplasm. (NCT00065507)
Timeframe: On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up.

,
Interventionparticipants (Number)
Any Adverse EventsHepatic Neoplasm, MalignantBasal Cell CarcinomaLymph Node Cancer, MetastaticHepatic Mass
Adefovir (ADV) 10 mg1818000
Entecavir (ETV) 1.0 mg1412111

[back to top]

Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data

Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 48 data set was used to evaluate the Week-48 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. (NCT00065507)
Timeframe: Week 48=all on-treatment laboratory measurements up to Week 48. Cumulative data = on-treatment laboratory measurements obtained after the start of therapy and no more than 5 days after the last dose of study therapy.

,,,
Interventionparticipants (Number)
HemoglobinInternational Normalized RatioPlatelet CountProthrombin TimeBicarbonate, LowChloride, Serum, LowBicarbonate/Carbon Dioxide, LowPotassium, Serum, HighSodium, SerumSodium, Serum, LowLipase, Total (colorimetric assay)Alanine Aminotransferase (ALT)AlbuminAlkaline Phosphatase (ALP)Aspartate Aminotransferase (AST)Bilirubin, TotalG-Glutamyl Transferase (GGT)Glucose, Fasting Serum, HighCreatininePhosphorus, inorganicBlood, urineGlucose, urineProtein, urineNeutrophils (relative)Neutrophils + Bands (relative)Neutrophils (absolute)
Cumulative - Adefovir (ADV) 10 mg10322411424055254317251000622134187
Cumulative - Entecavir (ETV) 1.0 mg1140252542416623591924912018172045
Week 48 - Adefovir (ADV) 10 mg82221742403318131318600413112143
Week 48 - Entecavir (ETV) 1.0 mg830202032316617390719101013111022

[back to top]

Change From Baseline in Platelet Count Through Week 48

Mean baseline platelet count and mean change from baseline in platelet count at specific timepoints. Platelets are the smallest particles found in the blood, which play a major role in forming blood clots. Normal range for platelets = 140 - 450 X 10*9 c/L. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Intervention10*9 c/L (Mean)
Baseline Value (n=97; n=91)Change at Week 4 (n=90; n=85)Change at Week 8 (n=82; n=76)Change at Week 12 (n=85; n=79)Change at Week 24 (n=77; n=76)Change at Week 36 (n=72; n=69)Change at Week 48 (n=68; n=63)
Adefovir (ADV) 10 mg93.31-2.143.88-0.81-2.891.323.05
Entecavir (ETV) 1.0 mg87.32-0.933.554.362.476.5610.19

[back to top]

Participants Achieving Albumin Normalization Through Week 48

Number of participants who achieved normalization of albumin (>= 1 x lower limit of normal [LLN]), a measure of liver function, at specific timepoints. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionparticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 36Week 48
Adefovir (ADV) 10 mg07611141420
Entecavir (ETV) 1.0 mg0296202932

[back to top]

Participants Achieving Platelet Count Normalization Through Week 48

Number of participants who achieved normalization of platelet count (>= 1 x lower limit of normal [LLN]), a measure of liver function, at specific timepoints. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionparticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 36Week 48
Adefovir (ADV) 10 mg0453221
Entecavir (ETV) 1.0 mg0337256

[back to top]

Participants Achieving Prothrombin Time Normalization Through Week 48

Number of participants who achieved normalization of prothrombin time (<= 1 x ULN), a measure of liver function, at specific timepoints. (NCT00065507)
Timeframe: Baseline, Week4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionparticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 36Week 48
Adefovir (ADV) 10 mg0443657
Entecavir (ETV) 1.0 mg03549108

[back to top]

Participants Achieving Total Bilirubin Normalization Through Week 48

Number of participants who achieved normalization of total bilirubin (<= 1 x ULN), a measure of liver function, at specific timepoints. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionparticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 36Week 48
Adefovir (ADV) 10 mg0999101718
Entecavir (ETV) 1.0 mg0410812915

[back to top]

Change From Baseline in HBV DNA by PCR at Week 48

Mean change from baseline in HBV DNA by PCR at Week 48, adjusted for baseline HBV DNA and LVDr Status. (NCT00065507)
Timeframe: Baseline, Week 48

Interventionlog10 copies/mL (Mean)
Entecavir (ETV) 1.0 mg-4.66
Adefovir (ADV) 10 mg-3.90

[back to top]

Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24

Mean reduction in serum HBV DNA determined by PCR assay (log10 copies/mL) at Week 24 adjusted for baseline HBV DNA and lamivudine resistance (LVDr) status, based on linear regression analysis. (NCT00065507)
Timeframe: Baseline, Week 24

Interventionlog10 copies/mL (Mean)
Entecavir (ETV) 1.0 mg-4.48
Adefovir (ADV) 10 mg-3.40

[back to top]

Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24

(NCT00065507)
Timeframe: Week 24

Interventionparticipants (Number)
Entecavir (ETV) 1.0 mg49
Adefovir (ADV) 10 mg15

[back to top]

Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48

(NCT00065507)
Timeframe: Week 48

InterventionParticipants (Number)
Entecavir (ETV) 1.0 mg57
Adefovir (ADV) 10 mg18

[back to top]

>=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48

Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
InterventionParticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 36Week 48
Adefovir (ADV) 10 mg0111011221925
Entecavir (ETV) 1.0 mg0142322323535

[back to top]

Change From Baseline in Albumin Through Week 48

Mean albumin levels, and mean change from baseline in albumin, a measure of synthetic liver function. Normal range for albumin = 3.5 - 5.3 g/dL. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventiong/dL (Mean)
Baseline Value (n=100; n=91)Change at Week 4 (n=98; n=88)Change at Week 8 (n=92; n=82)Change at Week 12 (n=88; n=80)Change at Week 24 (n=81; n=77)Change at Week 36 (n=76; n=70)Change at Week 48 (n=72; n=63)
Adefovir (ADV) 10 mg3.10-0.01-0.030.030.200.250.34
Entecavir (ETV) 1.0 mg3.00-0.040.010.050.260.360.49

[back to top]

Change From Baseline in Child-Pugh Score Through Week 48

Mean change from baseline in Child-Pugh score through week 48. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionunits on a scale (Mean)
Baseline Value (n=100, n=91)Change at Week 4 (n=90; n=85)Change at Week 8 (n=90; n=79)Change at Week 12 (n=87; n=80)Change at Week 24 (n=80; n=77)Change at Week 36 (n=75; n=70)Change at Week 48 (n=72; n=64)
Adefovir (ADV) 10 mg8.4-0.3-0.3-0.3-0.7-0.9-1.3
Entecavir (ETV) 1.0 mg8.8-0.4-0.4-0.6-1.2-1.6-1.7

[back to top]

Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL

AE=any new untoward medical occurrence/worsening of a pre-existing medical condition regardless of causal relationship. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires/prolongs inpatient hospitalization; results in persistent/significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. Confirmed increase in serum creatinine=values ≥0.5 mg/dL compared with baseline on 2 sequential measures. (NCT00065507)
Timeframe: on-treatment events obtained after the start of therapy and no more than 5 days after the last dose of study therapy.

,
Interventionparticipants (Number)
Any AEGrade 3/4 AEsSAEsDeathsHCCDiscontinuations due to AEsConfirmed creatinine increase >= 0.5 mg/dL
Adefovir (ADV) 10 mg8642592918521
Entecavir (ETV) 1.0 mg9155702312717

[back to top]

Improvement or No Worsening in MELD Score Through Week 48

Participants with improvement or no worsening (any decrease or no change from baseline in score) in MELD score through Week 48. The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; <10=4% mortality. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

,
InterventionParticipants (Number)
BaselineWeek 4Week 8Week 12Week 24Week 48
Adefovir (ADV) 10 mg05152605147
Entecavir (ETV) 1.0 mg05863676253

[back to top]

Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48

Adjusted mean change from baseline in MELD score through Week 48 (adjusted for baseline value). The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; <10=4% mortality. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionunits on a scale (Mean)
Baseline Value (n=100; n=91)Week 4 (n=97; n=87)Week 8 (n=90; n=79)Week 12 (n=88; n=80)Week 24 (n=80; n=77)Week 36 (n=75; n=70)Week 48 (n=72; n=62)
Adefovir (ADV) 10 mg15.30.1-0.4-0.9-0.9-1.2-1.7
Entecavir (ETV) 1.0 mg17.1-0.1-0.8-1.2-2.0-2.3-2.6

[back to top]

Mean Change From Baseline in Prothrombin Time Through Week 48

Mean prothrombin time, and mean change from baseline in prothrombin time, a measure of synthetic liver function. Prothrombin time is the time it takes (in seconds) for a sample of blood to clot. Normal range for prothrombin time (PT) = 10-13 seconds. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionseconds (Mean)
Baseline Value (n=100; n=91)Change at Week 4 (n=98; n=87)Change at Week 8 (n=91; n=79)Change at Week 12 (n=88; n=80)Change at Week 24 (n=80; n=77)Change at Week 48 (n=72; n=63)
Adefovir (ADV) 10 mg15.350.030.06-0.05-0.18-0.52
Entecavir (ETV) 1.0 mg16.28-0.08-0.10-0.29-0.75-0.99

[back to top]

Mean Change From Baseline in Total Bilirubin Through Week 48

Mean total bilirubin levels, and mean change from baseline in total bilirubin, a measure of liver secretory function.Normal range for total bilirubin = 0.2 - 1.2 mg/dL. (NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48

,
Interventionmg/dL (Mean)
Baseline Value (n=100; n=91)Change at Week 4 (n=98; n=88)Change at Week 8 (n=92; n=82)Change at Week 12 (n=88;l n=80)Change at Week 24 (n=81; n=77)Change at Week 36 (n=76; n=70)Change at Week 48 (n=72; n=63)
Adefovir (ADV) 10 mg2.500.21-0.17-0.28-0.14-0.09-0.10
Entecavir (ETV) 1.0 mg2.80-0.060.11-0.20-0.41-0.36-0.61

[back to top]

Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48

HCC-free survival was analyzed using life tables. Measured values show the number of HCC events among treated participants at given time points. (NCT00065507)
Timeframe: Week 48

,
InterventionHCC events (Number)
Weeks 0-4 (n=102; n=89)Weeks 4-8 (n=99; n=86)Weeks 8-12 (n=96; n=83)Weeks 12-16 (n=90; n=80)Weeks 16-20 (n=87; n=77)Weeks 20-24 (n=86; n=75)Weeks 24-28 (n=81; n=71)Weeks 28-32 (n=78; n=70)Weeks 32-36 (n=77; n=66)Weeks 36-40 (n=77; n=64)Weeks 40-44 (n=73; n=62)Weeks 44-48 (n=71; n=62)
Adefovir (ADV) 10 mg35691114151718202022
Entecavir (ETV) 1.0 mg2510111116171717192124

[back to top]

Number of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48

Number of participants in each group who achieved ALT normalization (≤1.0 x upper limit of normal [ULN]) among those with baseline ALT >1.0 x ULN at Weeks 24 and 48 (NCT00065507)
Timeframe: Week 24, Week 48

,
InterventionParticipants (Number)
Week 24Week 48
Adefovir (ADV) 10 mg2833
Entecavir (ETV) 1.0 mg4649

[back to top]

Percentage of Participants With Normal ALT at ADV Week 192 (Missing = Failure)

Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). Normal ALT: 0-1 year old = <=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L. (NCT00095121)
Timeframe: ADV Week 192

Interventionpercentage of participants (Number)
ADV - ADV14
PLB - ADV13

[back to top]

Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 192 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)

ADV baseline = 1st ADV-dose day = Week 0 for ADV-ADV group and Week 48 for PLB-ADV group. ADV week = windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). HBeAg loss is defined per individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and anti-HBe+ post baseline. (NCT00095121)
Timeframe: ADV baseline to ADV Week 192

,
Interventionpercentage of participants (Number)
HBeAg LossSeroconversion to Anti-HBe
ADV - ADV5644
PLB - ADV3311

[back to top]

Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 240 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)

Per protocol, participants could discontinue study medication due to HBeAg seroconversion and remain in the study in order to evaluate the durability of seroconversion. HBeAg loss is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and anti-HBe+ post baseline. (NCT00095121)
Timeframe: ADV baseline to ADV Week 240

Interventionpercentage of participants (Number)
HBeAg LossSeroconversion to Anti-HBe
ADV - ADV3317

[back to top]

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss or Seroconversion by End of Blinded Treatment (Study Week 48; Randomized and Treated Analysis Set)

HBeAg loss is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and hepatitis B e antibody + (anti-HBe+) post baseline. (NCT00095121)
Timeframe: Study Week 0 to Study Week 48 (double-blind period)

,
Interventionpercentage of participants (Number)
HBeAg LossSeroconversion to Anti-HBe
Adefovir Dipivoxil (ADV)1716
Placebo (PBL)55

[back to top]

Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal Alanine Aminotransferase (ALT) at Week 48 (Missing = Failure)

In the absence of biopsy data from these pediatric participants, this endpoint enables assessments of drug effect on viral replication and the underlying degree of inflammation in the liver. (NCT00095121)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
BaselineWeek 24Week 48 or End of Double-blind Treatment
Adefovir Dipivoxil (ADV)0519
Placebo (PLB)002

[back to top]

Adefovir (ADV) Baseline Serum HBV DNA

The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV [ADV-ADV group] and Week 48 for those originally randomized to placebo [PLB-ADV group]). (NCT00095121)
Timeframe: ADV baseline

Interventionlog10 HBV DNA copies/mL (Mean)
ADV - ADV8.76
PLB - ADV8.24

[back to top]

ADV Baseline ALT

The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV [ADV-ADV group] and Week 48 for those originally randomized to placebo [PLB-ADV group]). (NCT00095121)
Timeframe: ADV baseline

InterventionU/L (Mean)
ADV - ADV108.69
PLB - ADV99.81

[back to top]

Change From ADV Baseline to ADV Week 192 for ALT

Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). (NCT00095121)
Timeframe: ADV baseline to ADV 192 weeks

InterventionU/L (Mean)
ADV - ADV-66.06
PLB - ADV-38.88

[back to top]

Change From ADV Baseline to ADV Week 192 for Serum HBV DNA

Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). (NCT00095121)
Timeframe: ADV baseline to ADV 192 weeks

Interventionlog10 HBV DNA copies/mL (Mean)
ADV - ADV-5.89
PLB - ADV-5.41

[back to top]

Change From ADV Baseline to ADV Week 240 for ALT

(NCT00095121)
Timeframe: ADV baseline to ADV 240 weeks

InterventionU/L (Mean)
ADV - ADV-64.33

[back to top]

Change From ADV Baseline to ADV Week 240 for Serum HBV DNA

(NCT00095121)
Timeframe: ADV baseline to ADV 240 weeks

Interventionlog10 HBV DNA copies/mL (Mean)
ADV - ADV-5.87

[back to top]

Percentage of Participants With Durable HBeAg Seroconversion

A participant was defined to have durable HBeAg seroconversion only if she/he remained in a seroconverted state (HBeAg-, hepatitis B e antibody + [anti-HBe+]) from the date that she/he first seroconverted through and including her/his last study visit. This endpoint could only be assessed for participants who (HBeAg-) seroconverted on-treatment and subsequently discontinued open-label dosing. (NCT00095121)
Timeframe: 240 weeks

InterventionPercentage of participants (Number)
ADV - ADV82
PLB - ADV71

[back to top]

Percentage of Participants With Normal ALT at Adefovir Baseline (Missing = Failure)

The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV [ADV-ADV group] and Week 48 for those originally randomized to placebo [PLB-ADV group]). Normal ALT: 0-1 year old = <=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L. (NCT00095121)
Timeframe: ADV baseline

Interventionpercentage of participants (Number)
ADV - ADV7
PLB - ADV15

[back to top]

Percentage of Participants With Normal ALT at ADV Week 240 (Missing = Failure)

Normal ALT: 0-1 year old = <=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L. (NCT00095121)
Timeframe: ADV Week 240

Interventionpercentage of participants (Number)
ADV - ADV5

[back to top]

Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance) for Subjects Who Received Combination ADV + Lamivudine Therapy

Resistance surveillance was conducted at Week 240/last on-treatment study visit for all participants who had HBV DNA concentrations greater than or equal to the level of detection (>= 169 copies/mL) by PCR while on combination ADV + lamivudine treatment. (NCT00095121)
Timeframe: 240 weeks

,
InterventionParticipants (Number)
No genotypic changes from baselinePolymorphic site changesChanges at conserved sites in HBV polymeraseDeveloped mutations specific to ADV and/or LAMUnable to be genotyped
ADV - ADV53323
PLB - ADV11100

[back to top]

Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment - Missing = Failure) (ADV Week 192)

Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). (NCT00095121)
Timeframe: ADV Week 192

Interventionpercentage of participants (Number)
ADV - ADV15
PLB - ADV15

[back to top]

Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)

The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV [ADV-ADV group] and Week 48 for those originally randomized to placebo [PLB-ADV group]). (NCT00095121)
Timeframe: ADV baseline

Interventionpercentage of participants (Number)
ADV - ADV0
PLB - ADV0

[back to top]

Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)

(NCT00095121)
Timeframe: ADV Week 240

Interventionpercentage of participants (Number)
ADV - ADV6

[back to top]

Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)

The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV [ADV-ADV group] and Week 48 for those originally randomized to placebo [PLB-ADV group]). (NCT00095121)
Timeframe: ADV baseline

Interventionpercentage of participants (Number)
ADV - ADV0
PLB - ADV0

[back to top]

Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 192)

Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). (NCT00095121)
Timeframe: ADV Week 192

Interventionpercentage of participants (Number)
ADV - ADV11
PLB - ADV13

[back to top]

Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)

(NCT00095121)
Timeframe: ADV Week 240

Interventionpercentage of participants (Number)
ADV - ADV6

[back to top]

Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance)

Resistance surveillance was conducted annually for all participants who remained on treatment and had HBV DNA concentrations greater than or equal to the level of detection (>= 169 copies/mL) by PCR. The last on-ADV sample for all participants in the study was analyzed in the cumulative Week 240 resistance surveillance analysis. (NCT00095121)
Timeframe: 240 weeks

,
InterventionParticipants (Number)
No genotypic changes from baselinePolymorphic site changesChanges at conserved sites in HBV polymeraseDeveloped mutations specific to ADV/lamivudineUnable to be genotyped
ADV - ADV4817316
PLB - ADV1812304

[back to top]

HBV DNA Viral Kinetics - Spline Model

This analysis uses a 3-parameter piece-wise linear model and describes the biphasic decline in HBV DNA (measured by PCR assay) through Week 12. The 3 parameters are the values for the 2 slopes, describing the first and second phase declines, respectively, and the estimated HBV DNA at the knot (at day 10; the time point where the 2 phases join). The biphasic viral decay kinetics for each treatment were obtained using a spline fitting procedure to estimate the 3 parameters for each subject; these estimates were then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

,
Interventionlog10 copies/mL (Number)
First slope (first phase of viral decay)Second slope (second phase of viral decay)
Adefovir-0.329-0.024
Entecavir-0.391-0.034

[back to top]

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε) and effectiveness of the study treatment in blocking de novo infection of susceptible cells (η). The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

,
Interventionpercent effective (Number)
Efficacy in blocking virus production - εEffectiveness in blocking de novo infections - η
Adefovir99.465.87
Entecavir99.876.07

[back to top]

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the clearance rate of the free virus (c), the death rate of productively infected cells (δ), The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

,
Interventionper day (Number)
Viral Clearance - cInfected cell death - δ
Adefovir0.910.04
Entecavir1.700.08

[back to top]

Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs

Laboratory abnormalities reported as clinical AEs (NCT00096785)
Timeframe: Week 48

,
InterventionParticipants (Number)
ALT increasedLipase increasedBlood phosphorus decreasedLiver function test abnormalPlatelet count decreasedProtein urine present
Adefovir221111
Entecavir110000

[back to top]

Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths

AE=new untoward medical occurrence or worsening of pre-existing medical condition regardless of causal relationship to treatment. SAE=untoward medical occurrence that is life-threatening, a congenital anomaly/birth defect, or an important medical event, or results in death, inpatient hospitalization/prolongation of hospitalization, or persistent/significant disability. AE grades: mild (1), moderate (2), severe (3), life-threatening (4), death (5). ALT flare= >2x baseline & >10x ULN up to end of therapy + 5 days. Hepatic SAE=SAEs consistent with worsening of hepatitis or hepatic decompensation. (NCT00096785)
Timeframe: cumulative through the end of on-treatment observation as available at the time of the Week 48 dataset

,
InterventionParticipants (Number)
DeathSerious AEDiscontinuation due to AEMalignant neoplasmOn Treatment: Any AEOn Treatment: HeadacheOn Treatment: Upper Respiratory InfectionOn Treatment: InfluenzaOn Treatment: NasopharyngitisOn Treatment: PyrexiaOn Treatment: Back PainOn Treatment: Grade 3-4 AEsALT FlareHepatic SAE
Adefovir031027684665512
Entecavir010028986440201

[back to top]

Alanine Aminotransferase (ALT) Normalization

Number of participants with ALT ≤ 1 x upper limit of normal (ULN) (NCT00096785)
Timeframe: Week 48

Interventionparticipants (Number)
Entecavir25
Adefovir20

[back to top]

Change From Baseline in HBV DNA by PCR Assay at Week 48

Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 48, adjusted for baseline (Week 48 - Baseline). A negative value = improvement. (NCT00096785)
Timeframe: Baseline, Week 48

Interventionlog10 c/mL (Mean)
Entecavir-7.28
Adefovir-5.08

[back to top]

Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12

Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 12, adjusted for baseline (Week 12 - baseline). A negative value = improvement. (NCT00096785)
Timeframe: Baseline, Week 12

Interventionlog10 copies/mL (Mean)
Entecavir-6.23
Adefovir-4.52

[back to top]

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. An important derived parameter is the half-life of free virus (ie, the average amount of time for HBV particles in plasma to be reduced to half the initial level), calculated as 24*ln(2)/c. The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

Interventionhours (Number)
Entecavir14.52
Adefovir32.46

[back to top]

Viral Load Undetectable (HBV DNA <300 Copies/mL)

Number of Subjects with HBV DNA <300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL) (NCT00096785)
Timeframe: Week 48

InterventionParticipants (Number)
Entecavir19
Adefovir6

[back to top]

Percentage of Participants With HBV DNA Loss (<400 Copies/mL) at Week 52

The percentages of participants with an HBV DNA level in serum of less than 400 copies/mL, which is the lower limit of detection (HBV DNA loss) at Week 52 (NCT00316719)
Timeframe: Week 52

,
InterventionPercentage of participants (Number)
<400 copies/mL>400 copies/mL
Adefovir (ADV)46.054.0
Lamivudine (LAM)50.050.0

[back to top]

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 52

Participants with loss of Hepatitis B e antigen (HBeAg) in serum collected by blood draw: Cheminoluminescent Immuno Assay (CLIA) method (NCT00316719)
Timeframe: Week 52

,
Interventionpercentage of participants (Number)
With loss of HBeAgPositive for HBeAg
Adefovir (ADV)16.793.3
Lamivudine (LAM)16.293.8

[back to top]

Percentage of Participants With Hepatitis B e Antigen/Antibody (HBeAg/Ab) Seroconversion at Week 52

Participants with loss of Hepatitis B e antigen (HBeAg) and positive for anti-Hepatitis B e antibody (HBeAb) in serum collected by blood draw: CLIA method (NCT00316719)
Timeframe: Week 52

,
InterventionPercentage of participants (Number)
With HBeAg/Ab seroconversionWithout HBeAg/Ab seroconversion
Adefovir (ADV)9.790.3
Lamivudine (LAM)5.994.1

[back to top]

Percentage of Participants With Hepatitis B s Antigen (HBsAg) Loss at Week 52

Participants with loss of Hepatitis B s antigen (HBsAg) in serum collected by blood draw: CLIA method (NCT00316719)
Timeframe: Week 52

,
Interventionpercentage of participants (Number)
With loss of HBsAgPositive for HBsAg
Adefovir (ADV)0.0100.0
Lamivudine (LAM)0.0100.0

[back to top]

Percentage of Participants With Hepatitis B s Antigen/ Antibody (HBsAg/Ab) Seroconversion at Week 52

Participants with loss of Hepatitis B s antigen (HBsAg) and positive for anti-Hepatitis B s antibody (HBsAb) in serum collected by blood draw: CLIA method (NCT00316719)
Timeframe: Week 52

,
Interventionpercentage of participants (Number)
With HBsAg/Ab seroconversionWithout HBsAg/Ab seroconversion
Adefovir (ADV)0.0100.0
Lamivudine (LAM)0.0100.0

[back to top]

Rate of Emergence of Resistant Virus at Week 52

Participants with resistant mutation at Week 52. LAM resistant mutation (enzyme-linked mini-sequencing assay): rtM204I/V; ADV resistant mutation (direct sequencing assay): rtN236T or rtA181T/V in HBV DNA ; rt: reverse transcriptase gene (NCT00316719)
Timeframe: Week 52

,
InterventionPercentage of participants (Number)
With resistant mutationWithout resistant mutation
Adefovir (ADV)0100
Lamivudine (LAM)28.871.2

[back to top]

Mean Alanine Aminotransferase (ALT) Level at Week 52

Summary statistics were displayed for serum ALT. (NCT00316719)
Timeframe: Week 52

InterventionUnits per Liter (Mean)
Adefovir (ADV)32.3
Lamivudine (LAM)33.0

[back to top]

Mean Change From Baseline in Hepatitis B Virus (HBV) DNA at Week 52

Change from baseline was the difference of the HBV DNA copy numbers (log10) in serum collected by blood draw between baseline and Week 52 (NCT00316719)
Timeframe: Baseline and Week 52

Interventionlog10 copies/mL (Mean)
Adefovir (ADV)-3.69
Lamivudine (LAM)-3.40

[back to top]

Time to Onset of ALT Normalization

Time to onset of ALT normalization was summarized using the Kaplan-Meier method. (NCT00316719)
Timeframe: From Baseline to Week 52

InterventionWeek 52 (Median)
Adefovir (ADV)12.0
Lamivudine (LAM)12.0

[back to top]

Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 52

ALT normalization was defined as an ALT value that was in the normal range (<= 45IU/L; upper limit of normal [ULN]) at Week 52 of the participants whose ALT values were abnormal (>45IU/L) at baseline (NCT00316719)
Timeframe: Week 52

,
InterventionPercentage of participants (Number)
With ALT normalizationWithout ALT normalization
Adefovir (ADV)82.617.4
Lamivudine (LAM)78.421.6

[back to top]

Number of Participants Achieving Histological Improvement After the 104-week Treatment

Histological improvement (defined as ≥2 point reduction in the Knodell necroinflammation score without worsening fibrosis) was assessed by 2 independent pathologists in the HBeAg-negative participants who underwent 2 sequential liver biopsies at baseline and week 104/withdrawal. The Knodell/histological activity index (HAI) scoring system represents the sum of scores for periportal, bridging necrosis (0-10: none=0, multilobular necrosis=10), interlobular degeneration and focal necrosis (0-4: none=0, marked=4), portal inflammation (0-4: none=0, marked=4), and fibrosis (0-4: none=0, cirrhosis=4) (NCT00324961)
Timeframe: Week 104

Interventionparticipants (Number)
Histological improvementNo histological changeHistological worsening
HBeAg- at Baseline211713

[back to top]

Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104

Hepatitis B Virus (HBV) DNA level is tested in blood serum by real-time Polymerase Chain Reaction with the lower limit of detection (LLD) as 300 copies/milliliter in a central laboratory. (NCT00324961)
Timeframe: Week 104

Interventionparticipants (Number)
HBV DNA ≤300 cp/mLHBV DNA > 300 cp/mL
HBeAg- at Baseline85403

[back to top]

Number of Participants Achieving HBV DNA ≤300 Copies/mL Over Time

Hepatitis B Virus (HBV) DNA level is tested in blood serum by real-time Polymerase Chain Reaction with the lower limit of detection (LLD) as 300 copies/milliliter in a central laboratory. (NCT00324961)
Timeframe: Weeks 13, 26, 39, 52, 65, 78, 91, and 104

Interventionparticipants (Number)
HBV DNA ≤300 cp/mL, Week 13, n=528HBV DNA ≤300 cp/mL, Week 26, n=525HBV DNA ≤300 cp/mL, Week 39, n=523HBV DNA ≤300 cp/mL, Week 52, n=522HBV DNA ≤300 cp/mL, Week 65, n=514HBV DNA ≤300 cp/mL, Week 78, n=513HBV DNA ≤300 cp/mL, Week 91, n=505HBV DNA ≤300 cp/mL, Week 104, n=488
HBeAg- at Baseline262350393413415415421403

[back to top]

Number of Participants With ADV-associated Resistance at Week 104

Week 104 serum samples from participants who reached a HBV DNA breakthrough were assessed for the development of ADV (Adefovir dipivoxil) mutations (N236T and A181V) in the HBV polymerase. HBV DNA breakthrough was defined as an increase in HBV DNA level by 1 log10 copies/mL or more from the treatment nadir during Weeks 0 to 104. (NCT00324961)
Timeframe: Week 104

Interventionparticipants (Number)
HBV DNA breakthroughADV-associated resistance
10 mg Adefovir Dipivoxil (ADV)779

[back to top]

Number of Participants Achieving Complete Response at Week 104

Complete response was defined as an HBV DNA level ≤ 300 copies/mL by the Roche COBAS AMPLICOR HBV MONITOR Test and ALT normalized for two consecutive visits at least 3 months apart. (NCT00324961)
Timeframe: Week 104

Interventionparticipants (Number)
10 mg Adefovir Dipivoxil (ADV326

[back to top]

Time to Protocol-defined Complete Response Over a 104-week Treatment Period

Time to response was defined as the time to participants achieving protocol-defined complete response at week 104 from baseline. Protocol-defined complete response was an HBV DNA level ≤ 300 copies/mL by Roche COBAS AMPLICOR HBV MONITOR Test and ALT normalized for two consecutive visits at least 3 months apart. (NCT00324961)
Timeframe: Baseline to Week 104

Interventiondays (Mean)
10 mg Adefovir Dipivoxil (ADV)301.6

[back to top]

Change From Baseline in Median Serum HBV DNA Over Time

The HBV DNA level was tested in blood serum by real-time PCR with the LLD as 300 copies/mL at baseline and Weeks 13, 26, 39, 52, 65, 78, 91, and 104 in a central laboratory. (NCT00324961)
Timeframe: Baseline and Weeks 13, 26, 39, 52, 65, 78, 91, and 104

Interventionlog10 copies/mL (Median)
Serum HBV DNA Reduction at week 13Serum HBV DNA Reduction at week 26Serum HBV DNA Reduction at week 39Serum HBV DNA Reduction at week 52Serum HBV DNA Reduction at week 65Serum HBV DNA Reduction at week 78Serum HBV DNA Reduction at week 91Serum HBV DNA Reduction at week 104
HBeAg- at Baseline-3.2-3.5-3.6-3.6-3.7-3.8-3.7-3.7

[back to top]

Liver Histology Scores in HBeAg Negative Participants With Two Sequential Liver Biopsies During the Period of 104 Weeks

The Knodell/histological activity index (HAI) scoring system that represents the sum of scores for periportal bridging necrosis (0-10: none=0, moderate piecemeal necrosis plus bridging necrosis=5, multilobular necrosis=10); interlobular degeneration and focal necrosis (0-4: none=0, marked=4); portal inflammation (0-4: none=0, marked=4) and fibrosis (0-4: none=0, fibrous portal expansion=1, bridging fibrosis=3, cirrhosis=4) was carried out by two independent pathologists in the HBeAg negative participants with 2 sequential liver biopsies during the period of 104 weeks. (NCT00324961)
Timeframe: Baseline to Week 104

InterventionPoints on a scale (Mean)
Knodell score at baselineKnodell score at week 104/withdrawalNecroinflammation score at baselineNecroinflammation score at week 104/withdrawalFibrosis score at baselineFibrosis score at week 104/withdrawal
HBeAg- at Baseline8.05.46.33.21.62.1

[back to top]

Number of Participants Achieving ALT Normalization at Week 104

Serum alanine aminotransferase (ALT) normalization was defined as a serum ALT level at or below the upper limit of the normal (ULN) range after a baseline value above the ULN, as determined using central laboratory ranges. (NCT00324961)
Timeframe: Week 104

Interventionparticipants (Number)
ALT normalizationALT non-normalization
HBeAg- at Baseline333102

[back to top]

Number of Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 104

HBsAg loss and HBsAg seroconversion (HBsAg loss and HBsAb detected) were assessed for all participants who were HBeAg negative at Weeks 0 and 104. Confirmed HBsAg loss was defined as undetectable HBeAg. (NCT00324961)
Timeframe: Week 104

Interventionparticipants (Number)
HBsAg lossHBsAg seroconversion
HBeAg- at Baseline10

[back to top]

Number of Participants With Histologic Improvement at Month 36 (Per Protocol Population)

The Ishak fibrosis score is a scoring system (ranging from 0 to 6) that measures the degree of fibrosis (scarring) of the liver, which is caused by chronic necroinflammation (an inflammatory process in the liver including or leading to death of liver cells). A score of 0 represents no fibrosis, and a score of 6 represents established cirrhosis. Participants were classified as improved if the Ishak fibrosis score at Month 36 was 1 or more points less from the Screening score. (NCT00347009)
Timeframe: Screening and Month 36

Interventionparticipants (Number)
Adefovir Dipivoxil 10 Milligrams (mg)52

[back to top]

Change From Baseline in Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level at Months 12, 24, and 36

The levels of HBV DNA in serum were measured using the Amplicor Cobas assay by Roche Diagnostics (detection limit 300 copies/milliliter [ml]). Changes from baseline in the serum HBV DNA level at Months 12, 24 and 36 were calculated as Month 12 minus baseline, Month 24 minus baseline, and Month 36 minus baseline respectively. Change is reported in log10 units. (NCT00347009)
Timeframe: Baseline and Months 12, 24, and 36

Interventionlog10 copies/ml (Mean)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)-4.557-4.536-4.454

[back to top]

Number of Participants Achieving Virological Response (HBV DNA Level <= 10^3 Copies/ml) at Months 12, 24, and 36

Virological response was defined as an HBV DNA level <= 10^3 copies/ml. (NCT00347009)
Timeframe: Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)9199102

[back to top]

Number of Participants Achieving Virological Response (HBV DNA Level <= 10^4 Copies/ml) at Months 12, 24, and 36

Virological response was defined as an HBV DNA level <= 10^4 copies/ml. (NCT00347009)
Timeframe: Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)110114109

[back to top]

Number of Participants Who Were HBeAg Positive at Baseline, With HBeAg Seroconversion at Months 12, 24, and 36

HBeAg seroconversion was defined as a decrease in HBeAg to undetectable levels and a gain of detectable levels of Hepatitis B envelope antibody (HBeAb). (NCT00347009)
Timeframe: Baseline and Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)101815

[back to top]

Number of Participants Who Were HBsAg Positive at Baseline, With HBsAg Seroconversion at Months 12, 24, and 36

HBsAg seroconversion was defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of Hepatitis B surface antibody (HBsAb). (NCT00347009)
Timeframe: Baseline and Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)000

[back to top]

Number of Participants Who Were Hepatitis B Envelope Antigen (HBeAg) Positive at Baseline and Developed Undetectable Levels of HBeAg at Months 12, 24, and 36

HBeAg positive was defined as the presence of a detectable level of HBeAg. (NCT00347009)
Timeframe: Baseline and Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)172728

[back to top]

Number of Participants Who Were Hepatitis B Surface Antigen (HBsAg) Positive at Baseline and Developed Undetectable Levels of HBsAg at Months 12, 24, and 36

HBsAg positive was defined as the presence of a detectable level of HBsAg. (NCT00347009)
Timeframe: Baseline and Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)000

[back to top]

Number of Participants With a Reduction From Baseline in the Child-Pugh Score by 2 Points or More at Months 12, 24, and 36

The Child-Pugh score (modified version for scoring prothrombin time against reference range) was used in the study to assess the prognosis of chronic liver disease, mainly cirrhosis. The score employs five clinical measures of liver disease: encephalopathy, ascites, albumin, prothrombin time, and bilirubin. Each measure is scored on a scale of 1-3, with 1 being normal and 3 indicating most severe derangement. The total score for the Child-Pugh assessment was calculated as the sum of the 5 contributing scores, with a score range of 5 (best prognosis) to 15 (worst prognosis). (NCT00347009)
Timeframe: Baseline and Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)021

[back to top]

Number of Participants With Alanine Aminotransferase (ALT) Normalization at Months 12, 24, and 36

ALT levels were measured as part of the liver function tests. Participants with ALT normalization at each visit were defined as those with a value below the upper limit of the normal (ULN) range for ALT provided by that site at the respective visit. (NCT00347009)
Timeframe: Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)879191

[back to top]

Number of Participants With Undetectable HBV DNA at Months 12, 24, and 36

Undetectable HBV DNA was defined as an HBV DNA level below the lower limit of detection (LLOD) of 300 copies/ml. (NCT00347009)
Timeframe: Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)839590

[back to top]

Number of Participants With Virological Breakthrough at Months 12, 24, and 36

Virological breakthrough was defined as an increase in serum HBV DNA levels by more than 1 log10 copies/ml from treatment nadir, i.e., the lowest HBV DNA value during the study. (NCT00347009)
Timeframe: Months 12, 24, and 36

Interventionparticipants (Number)
Month 12Month 24Month 36
Adefovir Dipivoxil 10 Milligrams (mg)31621

[back to top]

Number of Participants With Histologic Improvement at Month 36 (Intent-to-Treat Population)

The Ishak fibrosis score is a scoring system (ranging from 0 to 6) that measures the degree of fibrosis (scarring) of the liver, which is caused by chronic necroinflammation (an inflammatory process in the liver including or leading to death of liver cells). A score of 0 represents no fibrosis, and a score of 6 represents established cirrhosis. Participants were classified as improved if the Ishak fibrosis score at Month 36 was 1 or more points less from the Screening score. (NCT00347009)
Timeframe: Screening and Month 36

Interventionparticipants (Number)
Adefovir Dipivoxil 10 Milligrams (mg)52

[back to top]

Number of Participants With a Reduction From Screening of at Least 2 Points in the Knodell Necroinflammation Score at Month 36

The Knodell scoring system, also called the Histologic Activity Index (HAI), classifies liver biopsy specimens according to scores into 4 categories of histologic features: (I) periportal and/or bridging necrosis (scores from 0 to 10); (II) intralobular degeneration and focal necrosis (scores from 0 to 4); (III) portal inflammation (scores from 0 to 4); (IV) fibrosis (scores from 0 to 4). The Knodell necroinflammation score is the sum of scores from Parts I-III, hence a range of 0 to 18, and measures the degree of acute necroinflammatory activity in the liver. (NCT00347009)
Timeframe: Screening and Month 36

Interventionparticipants (Number)
Adefovir Dipivoxil 10 Milligrams (mg)64

[back to top]

Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response

"Serological response is defined as Loss of HBeAg (Hepatitis B e antigen) and Appearance of anti-HBe (Hepatitis B e antibodies); participant is HBeAg negative and anti-HBe positive.~Virological response was defined as having < 10^5 copies/mL of serum HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) by real-time PCR (Polymerase Chain Reaction).~Biochemical response was defined as acheiving normal levels of ALT (Alanine Aminotransferase) level in Units/L." (NCT00371761)
Timeframe: At Week 72 [for Pegylated interferon alfa-2b (PegIntron), at 48 weeks post PegIntron treatment for up to 24 weeks; for Adefovir, at 24 weeks post adefovir treatment for up to 48 weeks]

InterventionParticipants (Number)
PegIntron0
Adefovir0

[back to top]

Percentage of Participants Achieving Specified Clinical and Laboratory Safety Criteria

Undetectable HBV DNA = HBV DNA <300 copies/ml. Serum aminotransferase (ALT) normalization is defined as ALT within normal limits on 2 successive visits for a pt. with an elevated ALT level (>=1.0 x ULN) at baseline (BL). Hepatitis B e antigen (HBeAg) loss is defined as the loss of detectable serum HBeAg in a pt. who was HBeAg +ve at BL. HBeAg seroconversion is defined as HBeAg loss with detectable HBeAb. Hepatitis B surface antigen (HBsAg) loss is defined as the loss of detectable serum HBsAg in a pt. who was HBsAg +ve at BL. HBsAg seroconversion is defined as HBsAg loss with detectable HBsAb. (NCT00376259)
Timeframe: 12 week, 24 week, 48 week and 60 weeks

,
InterventionPercentage of participants (Number)
Undetectable HBV DNA at week 12Undetectable HBV DNA at week 24Undetectable HBV DNA at week 48Undetectable HBV DNA at week 60Serum ALT normalization at week 12Serum ALT normalization at week 24Serum ALT normalization at week 48Serum ALT normalization at week 60HBeAg loss at week 12HBeAg loss at week 24HBeAg loss at week 48HBeAg loss at week 60HBeAg seroconversion at week 12HBeAg seroconversion at week 24HBeAg seroconversion at week 48HBeAg seroconversion at week 60HBsAg loss at week 12HBsAg loss at week 24HBsAg loss at week 48HBsAg loss at week 60HBsAg seroconversion at week 12HBsAg seroconversion at week 24HBsAg seroconversion at week 48HBsAg seroconversion at week 60
Adefovir Monotherapy5.010.00.00.025.035.033.30.00.05.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Combination Therapy4.815.038.50.040.055.069.250.00.05.023.10.00.00.015.40.00.00.00.00.00.00.00.00.0

[back to top]

Change From Baseline in Mean Hepatitis B Virus (HBV) DNA Concentration

Efficacy was assessed by the change from baseline in mean HBV DNA concentration after 12, 24, 48 and 60 weeks of treatment. (NCT00376259)
Timeframe: Baseline to 12 weeks, 24 weeks, 48 weeks and 60 weeks

,
InterventionLog10 Copies/mL (Mean)
At Baseline (N = 21, 20)At Week 12Change from Baseline to Week 12At Baseline (N = 20, 20)At Week 24Change from Baseline to Week 24At Baseline (N = 13, 9)At Week 48Change from Baseline to Week 48At Baseline (N = 2, 3)At Week 60Change from Baseline to Week 60
Adefovir Monotherapy10.1275.515-4.61210.1275.161-4.96610.2075.272-4.93410.0974.330-5.767
Combination Therapy10.2404.405-5.83510.2793.678-6.60110.6523.274-7.3789.6053.360-6.245

[back to top]

Number of Participants With HBeAg Loss, HBeAg Seroconversion, HBsAg Loss and HBsAg Seroconversion at Week 104 & 156

Hepatitis B e antigen (HBeAg) loss, HBeAg seroconversion (defined as HBeAg negative and hepatitis B e antibody [HBeAb] positive), hepatitis B surface antigen (HBsAg) loss and HBsAg seroconversion (defined as HBsAg negative and hepatitis B surface antibody [HBsAb] positive). HBeAg and HBsAg seroconversion are defined as the loss (becoming negative) of HBeAg and the concurrent appearance of antibodies against HBeAg and the loss of HBsAg and the concurrent appearance of antibodies against HBsAg, respectively. (NCT00403585)
Timeframe: Week 104 and 156

InterventionParticipants (Number)
Week 104 HBeAg loss, n=77Week 104 HBeAg seroconversion, n=77Week 104 HBsAg loss, n=77Week 104 HBsAg seroconversion, n=77Week 156 HBeAg loss, n=73Week 156 HBeAg seroconversion, n=73Week 156 HBsAg loss, n=73Week 156 HBsAg seroconversion, n=73
Adefovir Dipivoxil23600271210

[back to top]

Hepatitis B Virus (HBV) DNA (log10 Copies/mL) Change From Baseline at Week 156 of Adefovir Therapy

HBV DNA was tested with Roche Cobas Amplicor HBV monitor test, Lower Limit of Detection 300 copies/mL) after 3 years (156 weeks: Weeks 1-52 in Study ADF103814; Weeks 53-156 in Study 108005) of adefovir therapy). Change from baseline was calculated as the Week 156 value minus the Baseline value. Baseline is defined as the first day of study ADF103814, of which Study 108005 is an extension. (NCT00403585)
Timeframe: Baseline, Week 156

Interventionlog10 copies/mL (Mean)
Baseline, n=104Week 156, n=74Change from Baseline
Adefovir Dipivoxil7.943.89-4.16

[back to top]

Safety Assessment: Number of Participants With a Serious Adverse Event and an Adverse Event

The number of participants with a serious adverse event and an adverse event is reported. Refer to the adverse event section for details. (NCT00403585)
Timeframe: Treatment Phase (Weeks 53-156)

Interventionparticipants (Number)
Serious adverse eventAdverse event
Adefovir Dipivoxil243

[back to top]

Number of Participants Achieving ALT Normalization at Week 104 & 156

Alanine aminotransferase (ALT) normalization is defined as a value <= upper limit of normal (ULN) range based on the set of subjects with ALT>ULN at baseline. The normal range for ALT is 0-40 Units/Liter. (NCT00403585)
Timeframe: Week 104, Week 156

InterventionParticipants (Number)
Week 104, n=77Week 156, n=73
Adefovir Dipivoxil6365

[back to top]

Number of Participants Achieving Virological Response at Week 104 & 156

Virological response is defined as HBV DNA level<300 copies/ml (NCT00403585)
Timeframe: Week 104, Week 156

InterventionParticipants (Number)
Week 104, n=77Week 156, n=73
Adefovir Dipivoxil2024

[back to top]

HBV DNA Levels at Each Collection Time Point From Baseline Through Week 156

Serum HBV DNA. Baseline is defined as the first day of study ADF103814, of which Study 108005 is an extension. (NCT00403585)
Timeframe: Baseline, Weeks 68, 80, 92, 104, 120, 132, 144, 156

Interventionlog 10 copies/mL (Mean)
Baseline, n=104Week 68, n=74Week 80, n=73Week 92, n=77Week 104, n=76Week 120, n=76Week 132, n=78Week 144, n=74Week 156, n=73
Adefovir Dipivoxil7.943.903.793.993.973.883.933.973.89

[back to top]

Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. HBV DNA < 50 IU/mL = approximately 300 copies/mL. Percentage n/N: n= number of participants with HBV DNA <50 IU/mL; N = number of participants analyzed. (NCT00410202)
Timeframe: Week 96

InterventionPercentage of participants (Number)
ETV+ADV Combination Therapy43.5
ETV Monotherapy39.3
ADV+LVD Combination Therapy28.5

[back to top]

Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week. (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy0.7
ETV Monotherapy0
ADV+LVD Combination Therapy0.7

[back to top]

Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week. (NCT00410202)
Timeframe: Week 96

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy0
ETV Monotherapy0
ADV+LVD Combination Therapy0

[back to top]

Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay. HBV DNA less than (<)50 International units per milliliter (IU/mL) = approximately 300 copies/mL. Percentage of participants calculated n/N; n= number of participants with HBV DNA <50 IU/mL; N = number of participants analyzed. (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy25.4
ETV Monotherapy16.4
ADV+LVD Combination Therapy19.7

[back to top]

Change in Mean log10 From Baseline in HBV DNA at Week 48

HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load, negative values means reduction. (NCT00410202)
Timeframe: Baseline, Week 48

,,
Interventionlog10 (IU/mL (Mean)
HBV DNA at Week 48Change from baseline
ADV+LVD Combination Therapy3.36-4.11
ETV Monotherapy4.01-3.35
ETV+ADV Combination Therapy2.79-4.65

[back to top]

Cumulative Probability of Emergent Genotypic Resistance at Year 1

"yr=year. Cumulative probability (CP): Ptotal=1-(1-Pyr1)*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An event is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only)." (NCT00410202)
Timeframe: Year 1

,,
Interventionpercentage of participants (Number)
ETVr : n=134, 134, 134ADVr /TDFr : n=137, 137, 135ETVr or TDFr/ADVr : n=133, 132, 132ETVr and TDFr/ADVr : n=138, 139, 137ETVr with VBT: n=134, 134, 134ADVr /TDFr with VBT: n=137, 137, 135ETVr or ADVr/TDFr with VBT: n=133, 132, 132ETVr and ADVr/TDFr with VBT: n=138, 139, 137
ADV+LVD Combination Therapy0.71.52.300000
ETV Monotherapy30.73.800.700.80
ETV+ADV Combination Therapy00.70.800000

[back to top]

Cumulative Probability of Emergent Genotypic Resistance at Year 2

"Cumulative probability (CP): Ptotal=1-(1-Pyr1)*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An event is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only)." (NCT00410202)
Timeframe: Year 2

,,
Interventionpercentage of participants (Number)
ETVr : n=130, 128, 131ADVr/TDFr : n=132, 134, 131ETVr or ADVr/TDFr : n=128, 125, 127ETVr and ADVr/TDFr : n=134, 137, 135ETVr with VBT: n=130, 128, 131ADVr/TDFr with VBT: n=132, 134, 131ETVr or ADVr/TDFr with VBT: n=128, 125, 127ETVr and ADVr/TDFr with VBT: n=134, 137, 135
ADV+LVD Combination Therapy1.52.23.800000
ETV Monotherapy9.81.510.70.76.20.76.30.7
ETV+ADV Combination Therapy0.80.71.500000

[back to top]

Number of Participants With Laboratory Abnormalities: Serum Chemistry

ULN=upper limit of normal (Normal ranges are Central lab data and vary according to the site). ALT:>1.25*ULN, AST:>1.25*ULN, ALP:>1.25*ULN, Total Bilirubin:>1.1*ULN, Serum Lipase:>1.10*ULN, Creatinine:>1.1*ULN, Blood Urea Nitrogen:1.25*ULN, Hyperglycemia:>116 mg/dL, Hypoglycemia:<64 mg/dL, Hyponatremia:<132meq/L, Hypokalemia:<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, <3 g/dL; Hypernatremia:>148 meq/L, Hyperkalemia:>5.6 meq/L, Hypokalemia:<3.4 meq/L, Hyperchloremia:>113 meq/L, Hypochloremia:<93 meq/L; ALT flare: on treatment (OT), >2*Baseline and >10*ULN; off treatment (OF), 2*end of dosing value and >10*ULN (NCT00410202)
Timeframe: On treatment : Day 1 through Week 100 + 5 days; Offtreatment = End of OT period through 24 weeks

,,
Interventionparticipants (Number)
Alanine aminotransferase (ALT)Aspartate aminotransferase (AST)Alkaline Phosphatase (ALP)AlbuminSerum LipaseCreatinineBlood Urea NitrogenHyperglycemiaHypoglycemiaHypernatremiaHyponatremiaHyperkalemiaHypokalemiaHyperchloremiaHypochloremiaALT flare - OntreatmentALT flare - Offtreatment
ADV+LVD Combination Therapy7453612442379100521020
ETV Monotherapy8362413321465100421020
ETV+ADV Combination Therapy7660812420399100341130

[back to top]

Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade 1 = mild, Grade 2= moderate, Grade 3 = severe, Grade 4 = life threatening/disabling, Grade 5 = death. (NCT00410202)
Timeframe: From start of study therapy through Week 100 + 5 days

,,
Interventionparticipants (Number)
DeathsSAEsDiscontinuations due to AEsAEsGrade 2-4 Related AEsGrade 3-4 Related AEs
ADV+LVD Combination Therapy11229219
ETV Monotherapy0172109127
ETV+ADV Combination Therapy011110125

[back to top]

Percentage of Participants With HBV DNA by PCR Category at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay. (NCT00410202)
Timeframe: Week 48

,,
Interventionpercentage of participants (Number)
< LOQ (29 IU/mL)LOQ to < 5050 to < 172172 to < 1,7201,720 to < 17,20017,200 to < 172,000>= 172,000Missing
ADV+LVD Combination Therapy16.82.95.812.431.424.84.41.5
ETV Monotherapy13.62.92.97.922.125.723.61.4
ETV+ADV Combination Therapy25.408.026.128.38.00.73.6

[back to top]

Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)

HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy7.2
ETV Monotherapy6.5
ADV+LVD Combination Therapy5.9

[back to top]

Percentage of Participants With HBV DNA by PCR Category at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. (NCT00410202)
Timeframe: Week 96

,,
Interventionpercentage of participants (Number)
< LOQ (29 IU/mL)LOQ to < 5050 to < 172172 to < 1,7201,720 to < 17,20017,200 to < 172,000>= 172,000Missing
ADV+LVD Combination Therapy25.52.95.818.224.813.92.95.8
ETV Monotherapy36.42.93.66.410.015.716.48.6
ETV+ADV Combination Therapy38.45.110.115.220.35.805.1

[back to top]

Change in Mean log10 From Baseline in HBV DNA at Week 96

HBV DNA was analyzed by PCR, using the Roche COBAS® TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load. (NCT00410202)
Timeframe: Baseline, Week 96

Interventionparticipants (Mean)
ETV+ADV Combination Therapy-5.06
ETV Monotherapy-4.17
ADV+LVD Combination Therapy-4.49

[back to top]

Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific. (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy20.3
ETV Monotherapy11.4
ADV+LVD Combination Therapy11.7

[back to top]

Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest amount or concentration of analyte in a sample, which can be reliably detected, but not necessarily quantified. (NCT00410202)
Timeframe: Week 96

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy33.3
ETV Monotherapy27.1
ADV+LVD Combination Therapy20.4

[back to top]

Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed. (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy25.4
ETV Monotherapy13.6
ADV+LVD Combination Therapy16.8

[back to top]

Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed. (NCT00410202)
Timeframe: Week 96

InterventionPercentage of participants (Number)
ETV+ADV Combination Therapy38.4
ETV Monotherapy36.4
ADV+LVD Combination Therapy25.5

[back to top]

Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48

ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 or 48 U/L. (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy75.6
ETV Monotherapy78.0
ADV+LVD Combination Therapy76.8

[back to top]

Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96

ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L. (NCT00410202)
Timeframe: Baseline, Week 96

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy76.9
ETV Monotherapy74.4
ADV+LVD Combination Therapy79.7

[back to top]

Number of Participants With Laboratory Abnormalities: Hematology

Criteria for hematology abnormalities were: Hemoglobin: <=11.0 g/dL; White Blood Cells: <4000/mm^3; Absolute Neutrophils (includes absolute bands): <1500/mm^3; Platelets: <=99,000/mm^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline. (NCT00410202)
Timeframe: From start of study through Week 100 + 5 days

,,
Interventionparticipants (Number)
HemoglobinWhite Blood CellsNeutrophilsPlateletsInternational Normalized Ratio
ADV+LVD Combination Therapy113815129
ETV Monotherapy94817147
ETV+ADV Combination Therapy85314138

[back to top]

Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)

HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week (NCT00410202)
Timeframe: Week 96

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy12.3
ETV Monotherapy10.7
ADV+LVD Combination Therapy13.9

[back to top]

Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)

HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb). (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy5.1
ETV Monotherapy2.9
ADV+LVD Combination Therapy3.7

[back to top]

Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)

HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb). (NCT00410202)
Timeframe: Week 96

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy7.2
ETV Monotherapy3.6
ADV+LVD Combination Therapy5.1

[back to top]

Percentage of Participants With HBsAg Seroconversion at Week 48

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb. (NCT00410202)
Timeframe: Week 48

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy0.7
ETV Monotherapy0
ADV+LVD Combination Therapy0

[back to top]

Percentage of Participants With HBsAg Seroconversion at Week 96

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb. (NCT00410202)
Timeframe: Week 96

Interventionpercentage of participants (Number)
ETV+ADV Combination Therapy0
ETV Monotherapy0
ADV+LVD Combination Therapy0

[back to top]

Number of HBeAg Positive Participants Achieving Histological Improvement at Week 48

Histological improvement (defined as a ≥2 point reduction in the Knodell necroinflammation score without worsening fibrosis) was accessed by two pathologists in HBeAg-positive participants undergoing liver biopsy at baseline and week 48/withdrawal. Knodell/Histological Activity Index (HAI) score = combined scores for necrosis, inflammation, and fibrosis and is the sum of scores for periportal bridging necrosis (0-10: none=0, multilobular necrosis=10), intralobular degeneration and focal necrosis and portal inflammation (0-4: none=0, marked=4), and fibrosis (0-4: none=0, cirrhosis=4). (NCT00441974)
Timeframe: Week 48

Interventionparticipants (Number)
Histological improvementNo histological improvement
HBeAg+ at Baseline4625

[back to top]

Change From Screening in Median Serum HBV DNA at Weeks 24 and 48

The HBV DNA level was tested in blood serum by real-time Polymerase Chain Reaction with the LLD (lower limit of detection) as 300 copies/milliliter (cp/mL) at screening, week 24, and week 48 in a central laboratory. The change in HBV DNA from screening to week 24 and week 48 was conducted. (NCT00441974)
Timeframe: Weeks 24 and 48

,
Interventionlog10 copies/milliliter (Median)
Serum HBV DNA Change at Week 24Serum HBV DNA Change at Week 48
HBeAg- at Baseline-4.3-4.6
HBeAg+ at Baseline-4.1-4.6

[back to top]

Number of HBeAg Positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Week 48

HBeAg loss and HBeAg seroconversion (HBeAg loss and HBeAb detected) were assessed in participants who were HBeAg positive at Weeks 0 and 48. Confirmed HBeAg loss was defined as undetectable HBeAg. (NCT00441974)
Timeframe: Week 48

Interventionparticipants (Number)
HBeAg lossHBeAg seroconversion
HBeAg+ at Baseline289151

[back to top]

Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) <1000 Copies/Milliliter at Week 48

HBV (Hepatitis B Virus) DNA level was tested by real-time Polymerase Chain Reaction at Week 48. (NCT00441974)
Timeframe: Week 48

,,
Interventionparticipants (Number)
HBV DNA <1000 copies (cp)/mLHBV DNA >1000 cp/mL
HBeAg- at Baseline243116
HBeAg+ at Baseline341767
Total584883

[back to top]

Number of Participants With ADV-associated Resistance at Week 48

Week 48 serum samples from participants, who reached a HBV DNA breakthrough or have HBV DNA≥5 log copies/mL at Weeks 24 and 48 were assessed for the development of ADV (Adefovir dipivoxil) mutation (N236T and A181V) in the HBV polymerase. Virologic breakthrough was defined as an increase in the level of HBV DNA 1 log10 copy/mL from Week 24 to Week 48. ADV-associated resistance was defined as participants with both virologic breakthrough and ADV mutation. (NCT00441974)
Timeframe: Week 48

Interventionparticipants (Number)
HBV DNA breakthroughADV-associated resistanceHBV DNA≥5 log copies/ml at Weeks 24 and 48
10 mg Adefovir Dipivoxil667322

[back to top]

Ranked Assessment of Liver Histology in HBeAg Positive Participants From Baseline to Week 48

A ranked assessment with the Knodell/HAI scoring system that represents the sum of scores for periportal bridging necrosis (0-10: none=0, moderate piecemeal necrosis plus bridging necrosis=5, multilobular necrosis=10); interlobular degeneration and focal necrosis (0-4: none=0, marked=4); portal inflammation (0-4: none=0, marked=4) and fibrosis (0-4: none=0, fibrous portal expansion=1, bridging fibrosis=3, cirrhosis=4) was carried out by two pathologists in the HBeAg positive participants who underwent liver biopsy at baseline and Week 48/withdrawal. (NCT00441974)
Timeframe: Baseline to Week 48

Interventionpoints on a scale (Mean)
Knodell score at baselineKnodell score at Week 48/withdrawalNecroinflammation score at baselineNecroinflammation score at Week 48/withdrawalFibrosis score at baselineFibrosis score at Week 48/withdrawal
HBeAg+ at Baseline7.75.26.33.61.41.5

[back to top]

Number of Participants Achieving ALT (Alanine Aminotransferase) Normalization at Week 48

Elevated serum ALT levels are defined as serum ALT levels greater than the upper limit of the normal range (ULN), as determined using local laboratory ranges. ALT normalization was defined as ALT measurements at or below the ULN after a baseline value above the ULN. (NCT00441974)
Timeframe: Week 48

,
Interventionparticipants (Number)
ALT normalizationALT non-normalization
HBeAg- at Baseline258101
HBeAg+ at Baseline780328

[back to top]

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event. (NCT00605384)
Timeframe: Day 1 through end of treatment (Week 100 +/- 5 days)

,
Interventionparticipants (Number)
AEsSAEsDeathsDiscontinuations due to AEsDiscontinuations due to Laboratory Abnormalities
Adefovir + Continuing Lamivudine10000
Entecavir + Tenofovir10000

[back to top]

Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing

HBV DNA Level <50 IU/mL=approximately 300 copies/mL. (NCT00718887)
Timeframe: At Week 12 from Day 1

InterventionPercentage of participants (Number)
Entecavir, 0.5 mg QD5.6
Adefovir, 10 mg QD0.0

[back to top]

Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing

HBV=hepatitis B virus. HBV DNA Level <50 IU/mL=approximately 300 copies/mL. (NCT00718887)
Timeframe: At Week 48 from Day 1

InterventionPercentage of participants (Number)
Entecavir, 0.5 mg QD31.5
Adefovir, 10 mg QD/Entecavir, 0.5 mg QD28.6

[back to top]

Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing

HBV=hepatitis B virus (NCT00718887)
Timeframe: At Weeks 12 and 48 from Day 1

,
Interventionlog10 IU/mL (Mean)
Week 12 (n=88, 77)Week 48 (n=87, 71)
Adefovir, 10 mg QD/Entecavir, 0.5 mg QD-0.2-3.2
Entecavir, 0.5 mg QD-2.5-3.3

[back to top] [back to top]

Number of Participants With Genotypic Resistance to Entecavir

(NCT00718887)
Timeframe: At Week 48 from Day 1

,
InterventionParticipants (Number)
At baselineWeek 48
Adefovir, 10 mg QD/Entecavir, 0.5 mg QD00
Entecavir, 0.5 mg QD00

[back to top]

Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion

(NCT00718887)
Timeframe: At Weeks 12 and 48 from Day 1

,
InterventionParticipants (Number)
Week 12 HBsAg lossWeek 48 HBsAg lossWeek 12 HBsAg seroconversionWeek 48 HBsAg seroconversion
Adefovir, 10 mg QD/Entecavir, 0.5 mg QD0000
Entecavir, 0.5 mg QD0000

[back to top]

Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)

ULN=upper limit of normal. ALT normalization= ≤1*ULN, among participants with baseline ALT >1*ULN (NCT00718887)
Timeframe: At Weeks 12 and 48 from Day 1

,
InterventionPercentage of participants (Number)
Week 12 (n=51, 36)Week 48 (n=51, 36)
Adeforvi, 10 mg QD/Entecavir, 0.5 mg QD22.247.2
Entecavir, 0.5 mg QD31.460.8

[back to top]

Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results

Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes. (NCT00718887)
Timeframe: Day 1 through Week 48

,
InterventionPercentage of participants (Number)
Alanine aminotransferaseAspartate aminotransferaseHyperkalemiaHematology
Adefovir, 10 mg QD5.2010
Entecavir, 0.5 mg QD92.200

[back to top]

Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion

(NCT00718887)
Timeframe: At Weeks 12 and 48 from Day 1

,
InterventionPercentage of participants (Number)
HBeAG loss Week 12 (n=79, 72)HBeAG loss Week 48 (n=79, 72)HBe seroconversion Week 12 (n=79, 72)HBe seroconversion Week 48 (n=79, 72)
Adefovir, 10 mg QD/Entecavir, 10 mg QD6.96.91.452.8
Entecavir, 0.5 mg QD3.87.62.53.8

[back to top]

Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment

HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of hepatitis B e-antibody (anti-HBe/HBeAb) (a positive result for anti-HBe). (NCT00922207)
Timeframe: Week 100

Interventionpercentage of participants (Number)
Peg-IFN-Alfa-2a + Adefovir27.4
Peg-IFN-Alfa-2a + Entecavir29.5
Peg-IFN-Alfa-2a + Placebo36.3

[back to top]

Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

(NCT00922207)
Timeframe: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

,,
InterventionInternational Units/milliliter (IU/mL) (Mean)
Baseline (n=91,95,94)Change at Week 4 (n=90,94,92)Change at Week 8 (n=90,94,92)Change at Week 16 (n=90,94,92)Change at Week 28 (n=90,94,92)Change at Week 40 (n=90,94,92)Change at Week 52 (n=90,94,92)Change at Week 64 (n=90,94,92)Change at Week 76 (n=90,94,92)Change at Week 88 (n=90,94,92)Change at Week 100 (n=90,94,92)
Peg-IFN-Alfa-2a + Adefovir3.97-0.26-0.33-0.40-0.61-0.71-0.78-0.67-0.58-0.50-0.41
Peg-IFN-Alfa-2a + Entecavir3.76-0.18-0.31-0.49-0.68-0.67-0.69-0.54-0.45-0.44-0.60
Peg-IFN-Alfa-2a + Placebo3.84-0.02-0.25-0.48-0.70-0.82-0.88-0.67-0.53-0.62-0.56

[back to top]

Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

HBV DNA (copies per milliliter [copies/mL]) represented the viral load for Hepatitis B Virus (HBV), and was considered an indicator of viral replication. (NCT00922207)
Timeframe: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

,,
Interventioncopies/mL (Mean)
Baseline (n=91,95,94)Change at Week 4 (n=90,94,92)Change at Week 8 (n=90,94,92)Change at Week 16 (n=90,94,92)Change at Week 28 (n=90,94,92)Change at Week 40 (n=90,94,92)Change at Week 52 (n=90,94,92)Change at Week 64 (n=90,94,92)Change at Week 76 (n=90,94,92)Change at Week 88 (n=90,94,92)Change at Week 100 (n=90,94,92)
Peg-IFN-Alfa-2a + Adefovir8.65-2.15-1.87-2.14-2.34-2.61-2.75-1.87-1.91-1.78-2.00
Peg-IFN-Alfa-2a + Entecavir8.30-2.76-3.58-3.77-3.07-2.97-2.81-1.37-1.39-1.39-1.78
Peg-IFN-Alfa-2a + Placebo8.41-0.23-1.32-2.13-2.84-3.27-3.32-2.11-2.20-2.30-2.17

[back to top]

Percentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive

(NCT00922207)
Timeframe: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

,,
Interventionpercentage of participants (Number)
Baseline (n=91,95,94)Week 4 (n=90,94,92)Week 8 (n=90,94,92)Week 16 (n=90,94,92)Week 28 (n=90,94,92)Week 40 (n=90,94,92)Week 52 (n=90,94,92)Week 64 (n=90,92,92)Week 76 (n=88,88,92)Week 88 (n=86,87,90)Week 100 (n=84,87,91)
Peg-IFN-Alfa-2a + Adefovir0.00.00.00.00.00.00.00.00.01.20.0
Peg-IFN-Alfa-2a + Entecavir0.00.00.00.00.00.00.00.00.00.00.0
Peg-IFN-Alfa-2a + Placebo0.00.00.00.00.00.00.00.00.03.40.0

[back to top]

Percentage of Participant With Normal Alanine Aminotransferase (ALT) Levels

The normal range for ALT is 10 to 40 international units per liter (IU/L). (NCT00922207)
Timeframe: Baseline, Weeks 6, 12, 16, 22, 28, 34, 40, 46, 52, 64, 76, 88, and 100

,,
Interventionpercentage of participants (Number)
Baseline (n=91,95,94)Week 6 (n=90,93,92)Week 12 (n=90,93,92)Week 16 (n=90,93,92)Week 22 (n=90,93,92)Week 28 (n=90,93,92)Week 34 (n=90,93,92)Week 40 (n=90,93,92)Week 46 (n=90,93,92)Week 52 (n=90,93,92)Week 64 (n=90,92,92)Week 76 (n=89,89,92)Week 88 (n=86,88,91)Week 100 (n=84,88,91)
Peg-IFN-Alfa-2a + Adefovir4.44.415.621.125.626.726.730.030.033.332.243.832.636.9
Peg-IFN-Alfa-2a + Entecavir3.25.417.224.734.430.134.439.841.934.437.038.233.040.9
Peg-IFN-Alfa-2a + Placebo2.16.513.020.722.823.932.632.633.732.642.446.748.449.5

[back to top]

Percentage of Participants Who Were HBeAg Negative

(NCT00922207)
Timeframe: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

,,
Interventionpercentage of participants (Number)
Baseline (n=91,95,94)Week 4 (n=90,94,92)Week 8 (n=90,94,92)Week 16 (n=90,94,92)Week 28 (n=90,94,92)Week 40 (n=90,94,92)Week 52 (n=90,94,92)Week 64 (n=90,92,92)Week 76 (n=88,88,92)Week 88 (n=86,87,90)Week 100 (n=84,87,91)
Peg-IFN-Alfa-2a + Adefovir3.35.66.76.711.118.922.224.425.027.928.6
Peg-IFN-Alfa-2a + Entecavir2.14.36.48.510.618.122.325.028.427.632.2
Peg-IFN-Alfa-2a + Placebo0.01.14.310.916.322.829.331.537.034.437.4

[back to top]

Percentage of Participants With Combined Response

Combined response was defined as having negative HBeAg, HBV DNA less than (<) 100,000 copies/mL, and normal ALT level (10-40 IU/L). (NCT00922207)
Timeframe: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

,,
Interventionpercentage of participants (Number)
Baseline (n=91,95,94)Week 16 (n=90,93,92)Week 28 (n=90,93,92)Week 40 (n=90,93,92)Week 52 (n=90,93,92)Week 64 (n=90,92,92)Week 76 (n=88,89,92)Week 88 (n=86,88,91)Week 100 (n=84,88,91)
Peg-IFN-Alfa-2a + Adefovir0.00.00.00.00.02.23.43.52.4
Peg-IFN-Alfa-2a + Entecavir0.00.01.10.00.00.00.00.00.0
Peg-IFN-Alfa-2a + Placebo0.00.00.00.00.00.00.00.00.0

[back to top]

Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)

(NCT01023217)
Timeframe: at week 52 from randomization

Interventionparticipants (Number)
Adefovir Plus Entecavir13
Adefovir Plus Lamivudine2

[back to top]

Proportion of Patients With a Sustained Hepatitis B Surface Antibody Titer > 500 IU/mL Prior to and After Vaccination

(NCT01146808)
Timeframe: 12-18 months post transplant

InterventionParticipants (Count of Participants)
ADV Plus Hepatitis B Vaccination Group2

[back to top]

Proportion of Patients Who Develop de Novo Hepatitis B Infection Post ADV Withdrawal, Which Will be Assessed at 6 Months Post Withdrawal

(NCT01146808)
Timeframe: Six months after hepatitis B vaccination (2 years post transplant)

InterventionParticipants (Count of Participants)
ADV Plus Hepatitis B Vaccination Group3

[back to top]

Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver

Determined by positive hepatitis B serology (tests positive for HBsAg) and HBV DNA viral load (>40 IU/mL). (NCT01146808)
Timeframe: Standard of care visits post-transplant for 2 years

InterventionParticipants (Count of Participants)
ADV Plus Hepatitis B Vaccination Group5

[back to top]

Number of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.

Histological improvement is defined as a reduction of >=2 points in the KNS with no increase in fibrosis at Week 48 and Week 240 in participants with Baseline KNS >=2 which was derived from the American Association for the Study of Liver Diseases Practice Guidelines for Management of Chronic Hepatitis B (2009) and the European Association for the Study of the Liver Clinical Practice Guidelines Management of chronic hepatitis B virus infection (2012). The Knodell scale consists of 5 domains: periportal +/- bridging necrosis (scored from best to worst: 0, 1, 3, 4, 5, 6, or 10); intralobular degeneration and focal necrosis (0 to 4); portal inflammation (0 to 4); and fibrosis (0 to 4). The necroinflammatory score (ranging from 0 [best] to 14 [worst]) is the combined score for necrosis (0 to 10) plus inflammation (0 to 4; the participant is scored for only one inflammatory condition). Liver biopsy slides within 6 months prior to randomization could be accepted as Baseline evaluation. (NCT01300234)
Timeframe: Baseline; Week 48 and Week 240

,
InterventionParticipants (Number)
Week 48, HBeAg-positive, n=38, 49Week 48, HBeAg-negative, n=45, 50Week 240, HBeAg-positive, n=38, 49Week 240, HBeAg-negative, n=45, 50
ADV-TDF393424
TDF-TDF313258

[back to top]

Number of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)

TE grade 3 or grade 4 LAs are defined as values that increase by >=1 grade from Baseline (Day 0) to Grade 3 (severe) or 4 (potentially life threatening) at any post-Baseline value. The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Laboratory parameters assessed included Sodium for hyponatremia and hypernatremia; Potassium for hypokalemia and hyperkalemia; glucose for hypoglycemia and hyperglycemia non-fasting; Phosphate for hypophosphatemia; alanine aminotransferase/aspartate aminotransferase, bilirubin, creatinine kinase, hemoglobin, platelets, neutrophils, lymphocytes, prothrombin time and amylase. (NCT01300234)
Timeframe: Up to Week 240

,
Interventionparticipants (Number)
SodiumPhosphateAlanine aminotransferaseAspartate aminotransferaseBilirubinCreatine kinaseHemoglobinPlateletsNeutrophilsProthrombin timePotassiumGlucoseLymphocytesAmylase
ADV-TDF0314614534170232
TDF-TDF22191016446101121

[back to top]

Number of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus

The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Serum creatinine: Grade 1, > 133 to 177 micromoles per Liter (µmoles/Liter), Grade 2, >177 to 265 µmoles/Liter, Grade 3, >265 to 530 µmoles/Liter, Grade 4, >530 µmoles/Liter. Serum phosphorus: Grade 2, 0.63 to <0.80 millimoles per Liter (mmoles/L), Grade 3, 0.31 to <0.63 mmoles/L, Grade 4, <0.31 mmoles/L. The normal range for serum phosphorus was 0.8 to 1.45 mmoles/L; the upper limit for a Grade 2 abnormality is 0.80 mmoles/L. Therefore, no Grade 1 abnormalities could be attributed, as values were contained within the normal range. NA indicates the value was not available for the indicated time point. (NCT01300234)
Timeframe: Up to Week 240

,
InterventionParticipants (Number)
Serum creatinine, Grade 1Serum creatinine, Grade 2Serum creatinine, Grade 3Serum creatinine, Grade 4Serum phosphorus, Grade 1Serum phosphorus, Grade 2Serum phosphorus, Grade 3Serum phosphorus, Grade 4
ADV-TDF1000NA5530
TDF-TDF0000NA4220

[back to top]

Number of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240

"The number of HBeAg-positive and HBeAg-negative participants who had virological breakthrough at Weeks 48, 96, 144, 192 and 240 were assessed. Virological breakthrough is defined by >= one log increase in HBV DNA from NADIR (as determined by two sequential HBV DNA measurements at least one month apart or last on treatment measurement). A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Weeks 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 48,HBeAg-Positive, n=103, 99Week 48, HBeAg-Negative, n=154, 153Week 96, HBeAg-positive, n=103, 99Week 96, HBeAg-negative, n=154, 153Week 144, HBeAg-positive, n=103, 99Week 144, HBeAg-negative, n=154, 153Week 192, HBeAg-positive, n=103, 99Week 192, HBeAg-negative, n=154, 153Week 240, HBeAg-positive, n=103, 99Week 240, HBeAg-negative, n=154, 153
ADV-TDF42437475118
TDF-TDF0002030343

[back to top]

Participants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240

"The number of participants with HBV DNA <400 copies/mL in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. Week 96, 144, 192, and 240 data are not yet available, as this report includes data up to and including Week 48. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Weeks 96, 144, 192, and 240

,
InterventionParticipants (Number)
Week 96, HBeAg-positive, n=103, 99Week 96, HBeAg-negative, n=154, 153Week 144, HBeAg-positive, n=103, 99Week 144, HBeAg-negative, n=154,153Week 192, HBeAg-positive, n=103,99Week 192,HBeAg-negative, n=154,153Week 240, HBeAg-positive, n=103,99Week 240, HBeAg-negative, n=154,153
ADV-TDF92143951459314187137
TDF-TDF95144971449414487138

[back to top]

Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48

"The number of participants with Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) <400 copies/milliliter (mL) at Week 48 in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Week 48

,
InterventionParticipants (Number)
HBeAg-positive, n=103, 99HBeAg-negative, n=154, 153
ADV 10 mg18109
TDF 300 mg79149

[back to top]

Number of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240

"Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart from Week 96 to 240. This report includes data up to and including Week 240. A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Week 96 to Week 240

,
InterventionParticipants (Number)
HBeAg-positive, n= 88, 90HBeAg-negative, n = 132, 137
ADV-TDF01
TDF-TDF10

[back to top]

Number of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240

HBsAg loss is defined as negative HBsAg results for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 24, HBsAg lossWeek 24, HBsAg seroconversionWeek 48, HBsAg lossWeek 48, HBsAg seroconversionWeek 96, HBsAg lossWeek 96, HBsAg seroconversionWeek 144, HBsAg lossWeek 144, HBaAg seroconversionWeek 192, HBsAg, lossWeek 192, HBsAg, seroconversionWeek 240, HBsAg lossWeek 240 HBsAg seroconversion
ADV-TDF000000000000
TDF-TDF000000101010

[back to top]

Number of Participants in the Indicated Category for Renal Laboratory Abnormalities

"The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was used for grading. Confirmed is defined as two consecutive visits. mg=milligrams. dL=deciliter, G= Grade." (NCT01300234)
Timeframe: Up to Week 240

,
InterventionParticipants (Number)
Creatinine increase of 0.5 mg/dL above BaselineConfirmed creatinine >=2.0 mg/dLConfirmed clearance <50 milliliters/minuteConfirmed phosphorus G 3/4 abnormality, <2.0 mg/dL
ADV-TDF0000
TDF-TDF1003

[back to top]

Number of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.

HBeAg loss is defined as a negative HBeAg result for those participants who were HBeAg positive at Baseline. Seroconversion to anti-HBe is defined as HBeAg loss and a positive anti-HBe result. This report includes data up to and including Weeks 24, 48, 96, 144, 192 and 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 24, HBeAg lossWeek 24, HBeAg seroconversionWeek 48, HBeAg lossWeek 48, HBeAg seroconversionWeek 96, HBeAg lossWeek 96, HBeAg seroconversionWeek 144, HBeAg lossWeek 144, HBeAg seroconversionWeek 192, HBeAg lossWeek 192, HBeAg seroconversionWeek 240, HBeAg lossWeek 240, HBeAg seroconversion
ADV-TDF441092118242031243628
TDF-TDF151418163732373343334333

[back to top]

Number of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240

HBsAg loss is defined as a negative HBsAg result for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 24, HBsAg lossWeek 24, HBsAg seroconversionWeek 48, HBsAg lossWeek 48, HBsAg seroconversionWeek 96, HBsAg lossWeek 96, HBsAg seroconversionWeek 144, HBsAg lossWeek 144, HBsAg seroconversionWeek 192, HBsAg lossWeek 192, HBsAg seroconversionWeek 240, HBsAg lossWeek 240, HBsAg seroconversion
ADV-TDF000000110000
TDF-TDF000000000000

[back to top]

Change From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240

"Change from Baseline of log 10 copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240 in the HBeAg-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually a negative result indicates that the participant has lower levels of virus in the blood and less infectious. Values at Day 0 were considered as Baseline values. Change from Baseline was calculated as post Baseline values minus Baseline values. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Baseline, Weeks 48, 96, 144, 192 and 240

,
Interventionlog10 copies/mL (Mean)
Week 48,HBeAg-positive, n=102, 97Week 48,HBeAg-negative, n=151, 148Week 96, HBeAg-positive, n=101, 97Week 96, HBeAg-negative, n=147,148Week 144, HBeAg-postive, n=100, 96Week 144, HBeAg-negative, n=145, 146Week 192, HBeAg-positive, n=97,93Week 192, HBeAg-negative, n=145,145Week 240, HBeAg-positive, n=91,90Week 240, HBeAg-negative, n=138,138
ADV-TDF-4.4-4.3-6.5-4.8-6.5-4.9-6.6-4.8-6.5-4.9
TDF-TDF-6.4-4.9-6.5-4.9-6.6-4.9-6.6-4.9-6.6-4.9

[back to top]

Number of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48

"Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart. This report includes data up to and including Week 48. A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Week 24 to Week 48

,
InterventionParticipants (Number)
HBeAg-positive, n =100, 97HBeAg-negative, n=150, 147
ADV 10 mg00
TDF 300 mg00

[back to top]

Number of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline

"Participants who had abnormal ALT at Baseline and had normalized ALT at Weeks 48, 96, 144, 192 and 240 were assessed. This report includes data up to and including Weeks 48, 96, 144, 192 and 240. An increased level of ALT is referred to as abnormal ALT (the normal range is 0 to 48 units per liter [U/L]). Values at Day 0 were considered as Baseline values. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Baseline; Weeks 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 48, HBeAg-positive, n=102, 97Week 48, HBeAg-negative, n=136, 132Week 96, HBeAg-positive, n=102, 97Week 96, HBeAg-negative, n=136,132Week 144, HBeAg-positive, n=102, 97Week 144, HBeAg-negative, n=136, 132Week 192, HBeAg-positive, n=102, 97Week 192, HBeAg-negative, n=136,132Week 240, HBeAg-positive, n=102, 97Week 240, HBeAg-negative, n=136,132
ADV-TDF8311688118871197911880111
TDF-TDF8812093126921238912582119

[back to top]

Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is Grade 4 (life threatening or disabling). Participants with any non-serious AEs and SAEs has been reported. (NCT01300234)
Timeframe: Up to Week 240 treatment period and 24 weeks follow-up visit off treatment

,
InterventionParticipants (Number)
Non-serious AESAE
ADV-TDF12120
TDF-TDF14012

[back to top]

Number of Participants With a Serious Adverse Event

"A serious adverse event is any untoward medical occurrence that, at any dose: results in death /is life-threatening; requires hospitalization or prolongation of exixting hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is another medically significant event. For a list of all serious adverse events occurring during the course of the study, please see the table entitled Serious Adverse Events in the Adverse Event section of the results record." (NCT01329419)
Timeframe: 12 weeks

Interventionparticipants (Number)
Hepsera 10 mg Once a Day32

[back to top]

Number of Participants With an Adverse Event

"An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. For a list of all adverse events occurring during the course of the study, please see the table entitled Other (non-serious) adverse events in the Adverse Event section of the results record." (NCT01329419)
Timeframe: 12 weeks

Interventionparticipants (Number)
Hepsera 10 mg Once a Day74

[back to top]

Number of Participants With the Indicated Unexpected Adverse Events

An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Unexpected adverse events include those not listed in the approved product information and not described as precautions or warnings. (NCT01329419)
Timeframe: 12 weeks

Interventionparticipants (Number)
Sputum IncreasedHepatic CirrhosisHepatic EncephalopathyHepatic NeoplasmHypoaesthesiaHemoptysisAzotaemiaMarrow HyperplasiaMarrow DepressionFractureFasciitis NecrotisingSkin Reaction LocalisedMyalgiaResistanceProteinuriaEdema PeripheralDysuriaPancytopeniaAscitesSplenomegalyHernia InguinalEsophageal VaricesUrethral DisorderErythrocytes AbnormalVein VaricoseHemorrhage RectumGastric Ulcer HemorrhagicHematemesisPneumoniaPulmonary CarcinomaFatigueDyspneaJaundiceMelaena
Hepsera 10 mg Once a Day5427211111111111213111114111213121

[back to top]